Methods for treating Crohn's disease using anti-IL23 specific antibodies
Patent Information
- Application Number
- JP2024525067
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-29
- Filing Date
- 2022-10-27
- Publication Date
- 2024-11-13
AI Technical Summary
Current treatments for Crohn's disease using biologic agents like TNF antagonists and IL-12/23 inhibitors have limited efficacy, with a significant proportion of patients not responding over time, highlighting the need for new therapies with novel mechanisms to achieve and maintain long-term remission.
Administering an anti-IL23-specific antibody, such as guselkumab, in a specific dosage regimen starting from the beginning of treatment, with initial subcutaneous induction doses followed by regular maintenance doses to target IL-23, a cytokine implicated in Crohn's disease pathogenesis.
The method leads to significant improvements in clinical endpoints including reduced Crohn's Disease Activity Index, endoscopic and histological evaluations, and improved patient-reported outcomes, with potential for durable clinical remission and corticosteroid-free status.
Smart Images

Figure 2024541946000001_ABST
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention is directed to methods of treating Crohn's disease using antibodies that bind to human IL23. In particular, the present invention relates to dosing regimens for administering anti-IL23 specific antibodies and certain pharmaceutical compositions of the antibodies.
[0002] (Reference to electronically submitted sequence listing) This application contains a sequence listing that has been submitted electronically through the U.S. Patent and Trademark Office Patent Center as an XML sequence listing with the file name "JBI6635WOPCT1 Sequence Listing.xml", created on October 24, 2022, and size 11 kb. The sequence listing submitted through the Patent Center is a part of this specification and is incorporated by reference in its entirety herein.
[0003] BACKGROUND OF THEINVENTION Interleukin (IL)-12 is a secreted heterodimeric cytokine composed of two disulfide-linked glycosylated protein subunits (designated p35 and p40 for their approximate molecular weight). IL-12 is primarily produced by antigen-presenting cells and promotes cell-mediated immunity by binding to a two-chain receptor complex expressed on the surface of T cells or natural killer (NK) cells. The IL-12 receptor beta-1 (IL-12Rβ1) chain binds to the p40 subunit of IL-12, providing the primary interaction between IL-12 and its receptor. However, it is IL-12p35 ligation of the second receptor chain, IL-12Rβ2, that confers intracellular signaling (e.g., STAT4 phosphorylation) and activation of receptor-bearing cells (Presky et al, 1996). IL-12 signaling, concomitant with antigen presentation, is believed to trigger T cell differentiation towards the T helper 1 (Th1) phenotype, characterized by interferon gamma (IFNγ) production (Trinchieri, 2003). Th1 cells are believed to promote immunity against several intracellular pathogens, generate complementary antibody isotypes, and contribute to tumor immunosurveillance. Therefore, IL-12 is believed to be a critical component of the host defense immune mechanism.
[0004] It was discovered that the p40 protein subunit of IL-12 can also associate with a separate protein subunit designated p19 to form a novel cytokine, IL-23 (Oppman et al, 2000). IL-23 also signals through a two-chain receptor complex. As the p40 subunit is shared between IL-12 and IL-23, it follows that the IL-12Rβ1 chain is also shared between IL-12 and IL-23. However, it is IL-23p19 ligation of the second component of the IL-23 receptor complex, IL-23R, that confers IL-23-specific intracellular signaling (e.g., STAT3 phosphorylation) and subsequent IL-17 production by T cells (Parham et al, 2002; Aggarwal et al. 2003). Recent studies have shown that the biological functions of IL-23 and IL-12 are distinct, despite the structural similarities between these two cytokines (Langrish et al, 2005).
[0005] Abnormal regulation of IL-12 and Th1 cell populations has been implicated in many immune-mediated diseases, as neutralization of IL-12 with antibodies has been effective in treating animal models of psoriasis, multiple sclerosis (MS), rheumatoid arthritis, inflammatory bowel disease, insulin-dependent (type 1) diabetes mellitus, and uveitis (Leonard et al., 1995; Hong et al., 1999; Malfait et al., 1998; Davidson et al., 1998). However, these studies neutralized both IL-12 and IL-23 in vivo, as they targeted the common p40 subunit. Thus, it is unclear whether IL-12 or IL-23 mediated the disease, or whether both cytokines need to be inhibited to achieve disease suppression. Recent studies have confirmed that IL-23 inhibition can provide benefits comparable to anti-IL-12p40 strategies, either in IL-23p19-deficient mice or with specific antibody neutralization of IL-23 (Cua et al., 2003; Murphy et al., 2003; Benson et al., 2004). Thus, there is growing evidence for a specific role of IL-23 in immune-mediated diseases. Neutralizing IL-23 without inhibiting the IL-12 pathway could provide an effective treatment for immune-mediated diseases with limited impact on important host defense immune mechanisms. This would be a significant improvement over other therapeutic options.
[0006] Currently, there are three classes of biologic agents approved for the treatment of moderately to severely active Crohn's disease: tumor necrosis factor (TNF) antagonist therapies (infliximab, adalimumab, certolizumab), integrin inhibitors (natalizumab and vedolizumab), and IL-12 / 23 inhibitors (ustekinumab). Although the introduction of biologic agents has significantly improved the clinical management of patients with moderately to severely active Crohn's disease, a significant proportion of the study patient population does not respond or loses response over time. A review of the available data for the approved biologic agents highlights an unmet need in achieving and maintaining long-term remission, especially among patients who have previously failed biologic agents. In all treated patients (i.e., all patients randomized at week 0 of the evaluated studies), the estimated rate of clinical remission at 1 year is approximately 20% in the biologic agent failing or non-tolerant (BIO-failed) population and ranges from 20% to 50% in the conventional therapy failing or non-tolerant (CON-failed) population.
[0007] In summary, there remains a significant unmet medical need for new treatment options, particularly therapies with novel mechanisms of action that have the potential to raise the efficacy bar and maximize the proportion of patients who achieve and maintain clinical remission.
[0008] (Summary of the invention) In a first aspect, the present invention relates to a method of treating a subject suffering from Crohn's disease, comprising administering to the patient an anti-IL23 specific antibody (also referred to as IL23p19 or IL23p19 subunit antibody), e.g., guselkumab, as an initial subcutaneous induction dose from the start of treatment until week 4 from the start of treatment, followed by subcutaneous administration of an anti-IL-23 specific antibody once every 4 or 8 weeks thereafter, e.g., at weeks 0, 4, 8, 12 or 16, 20 or 24, 28 or 32, 36 or 40, 44 or 48. Moreover, in another embodiment, the subcutaneous treatment continues for 96 weeks or more after the start of treatment.
[0009] In one embodiment, the subject is administered an anti-IL23 specific antibody subcutaneously at a dose of 400 mg initially, 4 weeks after the initial dose, and 8 weeks after the initial dose, and continues treatment with an anti-IL23 specific antibody subcutaneously at a dose of 100 or 200 mg every 4 or 8 weeks through 24 weeks after the initial treatment, and optionally continuing beyond 24 weeks for up to 48 weeks, up to 96 weeks, and beyond.
[0010] In another aspect, the composition used in the method of the invention comprises a pharmaceutical composition comprising an anti-IL23 specific antibody. In a preferred embodiment, the anti-IL-23 specific antibody is guselkumab present in the following composition of pharmaceutical composition: 7.9% (w / v) sucrose, 4.0 mM histidine, 6.9 mM L-histidine monohydrochloride monohydrate; 0.053% (w / v) polysorbate 80, and the diluent is water at normal conditions.
[0011] In one embodiment, the anti-IL23 specific antibody is provided in a 200 mg / mL formulation in a single dose pre-filled syringe with a YpsoMate autoinjector (PFS-Y), and in an alternative embodiment, the anti-IL23 specific antibody is provided at 100 mg / mL in a single dose pre-filled syringe with an UltraSafe Plus™ Passive Needle Guard (PFS-U).
[0012] In one embodiment, the Crohn's disease patient achieves a significant improvement in a clinical endpoint selected from the following: (i) Change from baseline in Crohn's Disease Activity Index (CDAI) score; the CDAI score is assessed by collecting information on eight different Crohn's disease-related variables, with scores ranging from 0 to approximately 600. A decrease over time indicates improvement in disease activity; (ii) Patient-Reported Outcome (PRO)-2, defined by the unweighted CDAI components of total liquid or very loose stool count and abdominal pain (AP) score; (iii) endoscopic evaluation of the intestinal mucosa based on the presence or absence of mucosal ulceration and the Simple Endoscopic Score for Crohn's Disease (SES-CD); (iv) histological evaluation; (v) inflammatory pharmacodynamic (PD) markers, including C-reactive protein (CRP) or fecal calprotectin; (vi) fistula assessment; (vii) PRO measures to assess health-related quality of life outcomes, including the Inflammatory Bowel Disease Questionnaire (IBDQ) and Patient-reported Outcomes Measurement Information System (PROMIS)-29; (viii) patient-reported symptom scales, including the Bristol Stool Form Scale (BSFS) and AP-Numerical Rating Scale (NRS); (ix) Clinical remission at week 12, defined as a CDAI of less than (<) 150 points. (x) Clinical response at week 12, defined as a reduction from baseline in CDAI score of (≥) 100 points or a CDAI score of <150. (xi) Endoscopic response at week 12, as measured by the Simplified Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD is based on the assessment of four endoscopic components across five ileocolonic segments, with a total score ranging from 0 to 56. (xii) Endoscopic remission at week 12 as measured by Simplified Endoscopic Score for Crohn's Disease (SES-CD); SES-CD≦2. (xiii) clinical remission at week 48, defined as a CDAI score <150. (xiv) Sustained clinical remission at Week 48, defined as CDAI<150 for the majority of all visits between Weeks 12 and 48. (xv) Corticosteroid-free clinical remission at Week 48, defined as a CDAI score of <150 at Week 48 and no corticosteroids at Week 48. (xvi) PRO-2 remission at week 48, defined based on mean daily stool frequency (SF) and mean daily abdominal pain (AP) scores. Fatigue response at week 12, based on Patient-Reported Outcomes Measurement Information System (PROMIS). The Fatigue Short Form 7a contains seven items assessing the severity of fatigue, with higher scores indicating greater fatigue.
[0013] In another aspect of the invention, a pharmaceutical composition comprises an isolated anti-IL23 specific antibody having CDR sequences comprising: (i) heavy chain CDR amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and (ii) light chain CDR amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, optionally present in a composition of 7.9% (w / v) sucrose, 4.0 mM histidine, 6.9 mM L-histidine monohydrochloride monohydrate, 0.053% (w / v) polysorbate 80 of the pharmaceutical composition, and the diluent is standard water.
[0014] Another embodiment of the method of the invention comprises administering said pharmaceutical composition comprising an isolated anti-IL23 specific antibody having a heavy chain variable region amino acid sequence of SEQ ID NO:7 and a light chain variable region amino acid sequence of SEQ ID NO:8, optionally present in the following composition of pharmaceutical composition: 7.9% (w / v) sucrose, 4.0 mM histidine, 6.9 mM L-histidine monohydrochloride monohydrate, 0.053% (w / v) polysorbate 80, wherein the diluent is standard water.
[0015] A further aspect of the method of the invention comprises administering said pharmaceutical composition comprising an isolated anti-IL23 specific antibody having a heavy chain amino acid sequence of SEQ ID NO:9 and a light chain amino acid sequence of SEQ ID NO:10, optionally present in the following composition of pharmaceutical composition: 7.9% (w / v) sucrose, 4.0 mM histidine, 6.9 mM L-histidine monohydrochloride monohydrate, 0.053% (w / v) polysorbate 80, wherein the diluent is standard water.
[0016] In yet a further embodiment, the method of the invention comprises administering a pharmaceutical composition comprising the antibody guselkumab (sold as Tremfya® by Janssen Biotech, Inc.), optionally in the following composition of the pharmaceutical composition: 7.9% (w / v) sucrose, 4.0 mM histidine, 6.9 mM L-histidine monohydrochloride monohydrate, 0.053% (w / v) polysorbate 80, and the diluent is standard water.
[0017] The details of one or more embodiments of the invention are set forth in the description below. Other features and advantages will become apparent from the following detailed description, the drawings, and the appended claims. [Brief description of the drawings]
[0018] [Figure 1] FIG. 1 shows a schematic diagram of the study described herein. [Diagram 2] The dosing regimen for the treatment phase and how the study intervention will be administered are shown.
[0019] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS As used herein, methods of treating a subject suffering from Crohn's disease include administering isolated, recombinant, and / or synthetic anti-IL-23 specific human antibodies, as well as diagnostic and therapeutic compositions, methods, and devices.
[0020] As used herein, "anti-IL-23 specific antibodies," "anti-IL-23 antibodies," "antibody portions," or "antibody fragments," and / or "antibody variants," and the like, include any protein or peptide-containing molecule comprising at least a portion of an immunoglobulin molecule, such as, but not limited to, at least one complementarity determining region (CDR) or ligand binding portion thereof of a heavy or light chain, a heavy or light chain variable region, a heavy or light chain constant region, a framework region, or any portion thereof, or at least a portion of an IL-23 receptor or binding protein, that can be incorporated into an antibody of the invention. Such antibodies optionally further affect a specific ligand, for example, but not limited to, such antibodies modulate, reduce, enhance, antagonize, stimulate, reduce, ameliorate, block, inhibit, abrogate, and / or prevent at least one IL-23 activity or binding, or IL-23 receptor activity or binding, in vitro, in situ, and / or in vivo. As non-limiting examples, suitable anti-IL-23 antibodies, specified portions, or variants of the invention can bind to at least one IL-23 molecule or specified portions, variants, or domains thereof. Suitable anti-IL-23 antibodies, specified portions, or variants can also optionally affect at least one IL-23 activity or function, including, but not limited to, RNA, DNA, or protein synthesis, IL-23 release, IL-23 receptor signaling, membrane IL-23 cleavage, IL-23 activity, IL-23 production and / or synthesis, etc.
[0021] The term "antibody" is further intended to encompass antibodies, digested fragments thereof, specific portions, and variants, including antibody mimetics, or portions of antibodies that mimic the structure and / or function of antibodies, including single chain antibodies and fragments thereof, or specific fragments or portions thereof. Functional fragments include antigen-binding fragments that bind to mammalian IL-23. For example, Fab (e.g., by papain digestion), Fab' (e.g., by pepsin digestion and partial reduction), and F(ab')2 Antibody fragments capable of binding to IL-23 or a portion thereof, including, but not limited to, Fc' (e.g., by pepsin digestion), facb (e.g., by plasmin digestion), pFc' (e.g., by pepsin or plasmin digestion), Fd (e.g., by pepsin digestion, partial reduction and reassembly), Fv or scFv (e.g., by molecular biology techniques) fragments are encompassed by the present invention (see, e.g., Colligan, Immunology, supra).
[0022] Such fragments can be produced by enzymatic cleavage, synthetic, or recombinant techniques known in the art and / or described herein. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, F(ab') 2 The combination of genes encoding the heavy chain is H The antibody can be designed to contain DNA sequences encoding the antibody domain and / or hinge region. The various portions of the antibody can be joined chemically by conventional techniques, or can be prepared as a contiguous protein using genetic engineering techniques.
[0023] As used herein, the term "human antibody" refers to an antibody that is human and contains substantially all parts of the protein (e.g., CDRs, frameworks, C L , C H Domain (e.g., C H 1. C H 2. C H 3), Hinge (V L , V H)) that are substantially non-immunogenic in humans with only minor sequence changes or mutations. A "human antibody" may be an antibody derived from or closely corresponding to a human germline immunoglobulin sequence. A human antibody may contain amino acid residues not encoded in a germline immunoglobulin sequence (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). In many cases, this means that the human antibody is substantially non-immunogenic in humans. Human antibodies have been classified into groups based on the similarity of their amino acid sequences. Thus, using sequence similarity searches, antibodies with similar linear sequences can be selected as templates for creating human antibodies. Similarly, antibodies with names including primates (monkeys, baboons, chimpanzees, etc.), rodents (mouse, rats, rabbits, guinea pigs, hamsters, etc.), and other mammals designate antibodies specific for such species, subgenus, genus, subfamily, and family. Furthermore, chimeric antibodies can include any combination of the above. Such changes or mutations optionally and preferably retain or reduce immunogenicity in humans or other species compared to the unmodified antibody. Thus, a human antibody is distinct from a chimeric antibody or a humanized antibody.
[0024] It is noted that human antibodies can be produced by non-human animals or prokaryotic or eukaryotic cells capable of expressing functionally rearranged human immunoglobulin (e.g., heavy and / or light chain) genes. Furthermore, when the human antibody is a single-chain antibody, it can contain a linker peptide not found in naturally occurring human antibodies. For example, Fv can contain a linker peptide, such as 2 to about 8 glycine or other amino acid residues, connecting the variable region of the heavy chain and the variable region of the light chain. Such a linker peptide is considered to be of human origin.
[0025] Bispecific, heterospecific, heterobinding or similar antibodies may also be used, which are monoclonal, preferably human or humanized, antibodies with binding specificities for at least two different antigens, one of which is for at least one IL-23 protein and the other for any other antigen. Methods for producing bispecific antibodies are known in the art. Traditionally, recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-light chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature 305:537 (1983)). Due to the random combination of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a possible mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule (usually done by affinity chromatography steps) is quite laborious and the product yield is low. Similar procedures are described, for example, in WO 93 / 08829, U.S. Pat. Nos. 6,210,668, 6,193,967, 6,132,992, 6,106,833, 6,060,285, 6,037,453, 6,010,902, 5,989,530, 5,959,084, 5,959,083 ... ,932,448, 5,833,985, 5,821,333, 5,807,706, 5,643,759, 5,601,819, 5,582,996, 5,496,549, 4,676,980, WO 91 / 00360, WO 92 / 00373, EP 03089, Traunecker et al., EMBO J. 10:3655 (1991), and Suresh et al., Methods in Enzymology 121:210 (1986), each of which is incorporated herein by reference in its entirety.
[0026] Anti-IL-23 specific antibodies (also referred to as IL-23 specific antibodies) (or antibodies against IL-23) useful in the methods and compositions of the invention may optionally be characterized by high affinity binding to IL-23, and optionally and preferably low toxicity. In particular, antibodies of the invention, specific fragments or variants thereof, in which the individual components such as the variable region, constant region and framework, individually and / or collectively, optionally and preferably have low immunogenicity, are useful in the present invention. Antibodies that can be used in the present invention are optionally characterized by the ability to treat patients for extended periods of time with measurable alleviation of symptoms and low and / or acceptable toxicity. Low or acceptable immunogenicity and / or high affinity, as well as other favorable properties, can contribute to the therapeutic results obtained. "Low immunogenicity" is defined herein as raising a significant HAHA, HACA, or HAMA response in less than about 75%, or preferably less than about 50%, of treated patients, and / or raising low titers (less than about 300, preferably less than about 100, as measured by double antigen enzyme immunoassay) in treated patients (Elliott et al., Lancet 344:1125-1127 (1994), incorporated herein by reference in its entirety). "Low immunogenicity" may also be defined as the incidence of titratable levels of antibodies to an anti-IL-23 antibody in patients treated with an anti-IL-23 antibody when occurring in less than 25% of treated patients, preferably less than 10% of treated patients, at the recommended dose over the recommended course of treatment during the treatment period.
[0027] The term "safety", when referring to administration, dosing regimens, treatments, or methods of the present invention (e.g., the anti-IL-23 antibody guselkumab), refers to a relatively low or reduced frequency and / or low or reduced severity of treatment-emergent adverse events (also referred to as AEs or TEAEs) from clinical trials conducted, e.g., Phase 2 and earlier clinical trials, compared to a standard of care or another comparator. An adverse event is an untoward medical occurrence in a patient administered a medicinal product. In particular, when referring to administration, dosing regimens, or treatments with the present invention, clinically proven safety refers to a relatively low or reduced frequency and / or low or reduced severity of adverse events associated with administration of the antibody, when the cause is considered possible, probable, or highly likely to be due to the use of the anti-IL-23 antibody.
[0028] usefulness The isolated nucleic acids of the present invention can be used to generate at least one anti-IL-23 antibody or specific variants thereof, which can be used to measure or affect cells, tissues, organs, or animals (including mammals and humans) to diagnose, monitor, regulate, treat, alleviate, help prevent the occurrence of, or reduce the symptoms of Crohn's disease.
[0029] Such methods may include administering an effective amount of a composition or pharmaceutical composition comprising at least one anti-IL-23 antibody to a cell, tissue, organ, animal, or patient in need thereof to modulate, treat, alleviate, prevent, or reduce a symptom, effect, or mechanism. An effective amount may include an amount of about 0.001-500 mg / kg per single (e.g., bolus), multiple, or continuous administration, or an amount that achieves a serum concentration of 0.01-5000 μg / ml per single, multiple, or continuous administration, or any effective range or value therein, as performed and determined using known methods described herein or known in the relevant art.
[0030] References All publications or patents cited herein, whether specifically stated or not, are incorporated herein by reference in their entirety, indicating the prior art at the time of the invention and / or providing a description and enabling of the invention. A publication refers to any scientific publication or patent publication or any other information available in any media format, including all recorded in electronic or printed form. The following documents are incorporated herein by reference in their entirety: Ausubel, et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, NY (1987-2001); Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2 nd Edition, Cold Spring Harbor, NY(1989), Harlow and Lane, antibodies, a Laboratory Manual, Cold Spring Harbor, NY(1989), Colligan, et al., eds., Current Protocols in Immunology, John Wiley & Sons, Inc., NY(1994-2001), Colligan et al., Current Protocols in Protein Science, John Wiley & Sons, NY, NY, (1997-2001).
[0031] Antibodies of the invention - production and purification At least one anti-IL-23 used in the methods of the invention can optionally be produced by a cell line, mixed cell line, immortalized cell, or clonal population of immortalized cells, as known in the art, see, for example, Ausubel, et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, NY (1987-2001); Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2002; and U.S. Pat. No. 6,333,311, each of which is incorporated herein by reference in its entirety.nd Edition, Cold Spring Harbor, NY(1989), Harlow and Lane, antibodies, a Laboratory Manual, Cold Spring Harbor, NY(1989), Colligan, et al., eds., Current Protocols in Immunology, John Wiley & Sons, Inc., NY(1994-2001), Colligan et al., Current Protocols in Protein Science, John Wiley & See Sons, NY, NY, (1997-2001).
[0032] A preferred anti-IL-23 antibody is guselkumab (also known as CNTO1959), which has a heavy chain variable region amino acid sequence of SEQ ID NO:7 and a light chain variable region amino acid sequence of SEQ ID NO:8, and heavy chain CDR amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and light chain CDR amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. Other anti-IL-23 antibodies have the sequences listed herein and are described in U.S. Patent No. 7,935,344, the entire contents of which are incorporated herein by reference.
[0033] Human antibodies specific for human IL-23 protein or fragments thereof can be raised against suitable immunogenic antigens, such as isolated IL-23 protein and / or portions thereof (including synthetic molecules such as synthetic peptides). Other specific or general mammalian antibodies can be similarly generated. Preparation of immunogenic antigens and production of monoclonal antibodies can be performed using any suitable technique.
[0034] In one approach, a suitable immortal cell line (such as, but not limited to, Sp2 / 0, Sp2 / 0-AG14, NSO, NS1, NS2, AE-1, L.5, L243, P3X63Ag8.653, Sp2 SA3, Sp2 MAI, Sp2 SS1, Sp2 SA5, U937, MLA 144, ACT IV, MOLT4, DA-1, JURKAT, WEHI, K-562, COS, RAJI, NIH 3T3, HL-60, MLA 144, NAMALWA, NEURO Myeloma cell lines such as 2A, or heteromylomas, fusion products thereof, or any cells or fusion cells derived therefrom, or any other suitable cell line known in the art) (see, for example, www.atcc.org, www.lifetech.com, etc.), antibody producing cells such as isolated or cloned spleen, peripheral blood, lymph, tonsil, or other immune or B cell containing cells, or recombinant or endogenous viruses, as endogenous or heterologous nucleic acids, or any other cell expressing the heavy or light chain constant or variable, or framework, or CDR sequences, either as single, double, or triple stranded, hybridized, etc., or as any combination thereof, to produce a hybridoma. See, e.g., Ausubel, supra, and Colligan, supra, Immunology, Chapter 2, both of which are incorporated herein by reference in their entireties.
[0035] Antibody producing cells can also be obtained from the peripheral blood, or preferably the spleen or lymph nodes, of humans or other suitable animals immunized with the antigen of interest. Any other suitable host cells can also be used to express heterologous or endogenous nucleic acid encoding the antibodies of the invention, specific fragments or variants thereof. Fused cells (hybridomas) or recombinant cells can be isolated using selective culture conditions or other suitable known methods and cloned by limiting dilution or cell sorting or other known methods. Cells producing antibodies with the desired specificity can be selected by a suitable assay (e.g., ELISA).
[0036] Other methods suitable for producing or isolating antibodies with the required specificity can be used, including, but not limited to, recombinant antibody selection from peptide or protein libraries (e.g., display libraries such as, but not limited to, bacteriophage, ribosomal, oligonucleotide, RNA, cDNA, etc., available from, e.g., Cambridge Antibody Technologies, Cambridgeshire, UK; MorphoSys, Martinsreid / Planegg, DE; Biovation, Aberdeen, Scotland, UK; BioInvent, Lund, Sweden; Dyax Corp., Enzon, Affymax / Biosite, Xoma, Berkeley, CA, Ixsys.See, for example, European Patent No. 368,684, International Application No. GB91 / 01134, International Application No. PCT / GB92 / 01755, International Application No. PCT / GB92 / 002240, International Application No. PCT / GB92 / 00883, International Application No. PCT / GB93 / 00605, U.S. Patent Application Publication No. 08 / 350260 (5 / 12 / 94), International Application No. PCT / GB94 / 01422, ... PCT / GB94 / 02662, International Application No. PCT / GB97 / 01835, (CAT / MRC), WO 90 / 14443, WO 90 / 14424, WO 90 / 14430, International Application No. US94 / 1234, WO 92 / 18619, WO 96 / 07754 (Scripps), WO 96 / 13583, WO 97 / 08320 (M orphoSys), WO 95 / 16027 (BioInvent), WO 88 / 06630, WO 90 / 3809 (Dyax), U.S. Patent No. 4,704,692 (Enzon), International Application No. US91 / 02989 (Affymax), WO 89 / 06283, EP 371998, EP 550400, (Xoma), EP 22 9046, International Application US91 / 07149 (Ixsys), or stochastically generated peptides or proteins - U.S. Pat. Nos. 5,723,323, 5,763,192, 5,814,476, 5,817,483, 5,824,514, 5,976,862, WO 86 / 05803, EP 590689 (Ixsys), Applied Molecular Evolution (Applied These techniques include those based on the prior art of human immunodeficiency virus (HIV) immunotherapy, such as the American Association for Molecular Evolution (AME), a predecessor of the American Society for Clinical Immunology (ACS), each of which is incorporated herein by reference in its entirety), or rely on immunization of transgenic animals capable of producing a repertoire of human antibodies as known in the art and / or described herein (e.g., SCID mice, each of which is incorporated herein by reference in its entirety; Nguyen et al., Microbiol. Immunol. 41:901-907 (1997); Sandhu et al., Crit. Rev. Biotechnol. 16:95-118 (1996); Eren et al., Immunol.93:154-161 (1998), and related patents and applications. Such techniques include ribosome display (Hanes et al., Proc. Natl. Acad. Sci. USA, 94:4937-4942 (May 1997); Hanes et al., Proc. Natl. Acad. Sci. USA, 95:14130-14135 (Nov. 1998)), single cell antibody production techniques (e.g., the selected lymphocyte antibody method, "SLAM") (U.S. Pat. No. 5,627,052; Wen et al., J. Immunol. 17:887-892 (1987); Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-7848 (1996)), gel microdroplets and flow cytometry (Powell et al., J. Immunol. 1999, 11:111-111 (1998)). al., Biotechnol. 8:333-337 (1990); One Cell Systems, Cambridge, MA; Gray et al., J. Imm. Meth. 182:155-163 (1995); Kenny et al., Bio / Technol. 13:787-790 (1995)), B cell selectors (Steenbakkers et al., Molec. Biol. Reports 19:125-134 (1994); Jonak et al., Progress Biotech, Vol. 5, In Vitro Immunization in Hybridoma Technology, Borrebaeck, ed., Elsevier Science Publishers BV, Amsterdam, Netherlands (1988)).
[0037] Methods for engineering or humanizing non-human or human antibodies can also be used and are well known in the art. Typically, a humanized or modified antibody has one or more amino acid residues derived from a non-human source, such as, but not limited to, mouse, rat, rabbit, non-human primate, or other mammalian source. These non-human amino acid residues are replaced by residues often referred to as "import" residues, which are typically taken from an "import" variable, constant, or other domain of a known human sequence.
[0038] Known human Ig sequences are, for example, :www.ncbi.nlm.nih.gov / entrez / query.fcgi, www.ncbi.nih.gov / igblast, www.atcc.org / phage / hdb.html, www.mrc-cpe.cam.ac.uk / ALIGNMENTS.php;www.kabatdatabase.com / top.html, ftp.ncbi.nih.gov / repository / kabat;www.sciquest.com, www.abcam.com, www.antibodyresource.com / onlinecomp.html, www.public.iastate.edu / ~pedro / research_tools.html, www.whfreeman.com / immunology / CH05 / kuby05.htm, www.hhmi.org / grants / lectures / 1996 / vlab, www.path.cam.ac.uk / ~mrc7 / mikeimages.html, mcb.harvard.edu / BioLinks / Immunology.html;www.immunologylink.com, pathbox.wustl.edu / ~hcenter / index.html;www.appliedbiosystems.com, www.nal.usda.gov / awic / pubs / antibody, www.m.ehime-u.ac.jp / ~yasuhito / Elisa.html, www.biodesign.com, www.cancerresearchuk.org, www.biotech.ufl.edu, www.isac-net.org, baserv.uci.kun.nl / ~jraats / links1.html;www.recab.uni-hd.de / immuno.bme.nwu.edu, www.mrc-cpe.cam.ac.uk, www.ibt.unam.mx / vir / V_mice.html, http: / / www.bioinf.org.uk / abs, antibody.bath.ac.uk;www.unizh.ch, www.cryst.bbk.ac.uk / ~ubcg07s, www.nimr.mrc.ac.uk / CC / ccaewg / ccaewg.html, www.path.cam.ac.uk / ~mrc7 / humanisation / TAHHP.html, www.ibt.unam.mx / vir / structure / stat_aim.html, www.biosci.missouri.edu / smithgp / index.html, www.jerini.de, Kabat et al., Sequences of Proteins of Immunological Interest, USDept. Health (1983).
[0039] Such imported sequences can be used to reduce immunogenicity, or reduce, enhance, or modulate binding, affinity, binding rate constant, dissociation rate constant, avidity, specificity, half-life, or any other suitable characteristic, as known in the art. Generally, CDR residues directly and most substantially affect antigen binding. Thus, non-human sequences of variable and constant regions can be replaced with human amino acids or other amino acids, while maintaining some or all of the non-human or human CDR sequences.
[0040] The antibodies may optionally be humanized or human antibodies that have been genetically engineered while retaining high affinity for the antigen and other favorable biological properties. To this end, humanized (or human) antibodies may optionally be prepared by a process of analysis of the parental sequences and various theoretical humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available that illustrate and display probable three-dimensional conformations of selected candidate immunoglobulin sequences. Inspection of these displays allows analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., analysis of residues that affect the antigen-binding ability of the candidate immunoglobulin. In this way, framework (FR) residues can be selected and combined from the consensus and import sequences so that desired antibody properties, such as enhanced affinity for the target antigen, are achieved.
[0041] In addition, human IL-23 specific antibodies used in the methods of the invention may comprise a human germline light chain framework. In certain embodiments, the light chain germline sequence is selected from a human VK sequence, including, but not limited to, A1, A10, A11, A14, A17, A18, A19, A2, A20, A23, A26, A27, A3, A30, A5, A7, B2, B3, L1, L10, L11, L12, L14, L15, L16, L18, L19, L2, L20, L22, L23, L24, L25, L4 / 18a, L5, L6, L8, L9, O1, O11, O12, O14, O18, O2, O4, and O8. In certain embodiments, the light chain human germline framework is selected from V1-11, V1-13, V1-16, V1-17, V1-18, V1-19, V1-2, V1-20, V1-22, V1-3, V1-4, V1-5, V1-7, V1-9, V2-1, V2-11, V2-13, V2-14, V2-15, V2-17, V2-19, V2-6, V2-7, V2-8, V3-2, V3-3, V3-4, V4-1, V4-2, V4-3, V4-4, V4-6, V5-1, V5-2, V5-4, and V5-6.
[0042] In other embodiments, the human IL-23 specific antibodies used in the methods of the invention may comprise a human germline heavy chain framework. In certain embodiments, the heavy chain human germline framework is selected from the group consisting of VH1-18, VH1-2, VH1-24, VH1-3, VH1-45, VH1-46, VH1-58, VH1-69, VH1-8, VH2-26, VH2-5, VH2-70, VH3-11, VH3-13, VH3-15, VH3-16, VH3-20, VH3-21, VH3-23, VH3-30, VH3- 33, VH3-35, VH3-38, VH3-43, VH3-48, VH3-49, VH3-53, VH3-64, VH3-66, VH3-7, VH3-72, VH3-73, VH3-74, VH3-9, VH4-28, VH4-31, VH4-34, VH4-39, VH4-4, VH4-59, VH4-61, VH5-51, VH6-1, and VH7-81.
[0043] In certain embodiments, the light chain variable region and / or the heavy chain variable region comprises a framework region, or at least a portion of a framework region (e.g., comprising two or three subregions, such as FR2 and FR3). In certain embodiments, at least FRL1, FRL2, FRL3, or FRL4 is fully human. In other embodiments, at least FRH1, FRH2, FRH3, or FRH4 is fully human. In some embodiments, at least FRL1, FRL2, FRL3, or FRL4 is a germline sequence (e.g., human germline) or comprises a human consensus sequence for a particular framework (which are readily available at the sources of known human Ig sequences mentioned above). In other embodiments, at least FRH1, FRH2, FRH3, or FRH4 is a germline sequence (e.g., human germline) or comprises a human consensus sequence for a particular framework. In preferred embodiments, the framework regions are fully human framework regions.
[0044] Humanization or genetic engineering of the antibodies of the present invention may be carried out in accordance with the methods described by Winter (Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988); Verhoeyen et al., Science 239:1534 (1988)), Sims et al., J. Immunol. 151:2296 (1993), Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al., Proc. Natl. Acad. Sci. USA 89:4285 (1992), Presta et al. al., J.Immunol.151:2623 (1993), U.S. Patent No. 5723323, U.S. Patent No. 5976862, U.S. Patent No. 5824514, U.S. Patent No. 5817483, U.S. Patent No. 5814476, U.S. Patent No. 5763192, U.S. Patent No. 5723323, U.S. Patent No. 5,76 6886, 5714352, 6204023, 6180370, 5693762, 5530101, 5585089, 5225539, 4816567, International Application No. US98 / 16280, US9 This can be done using any known method, such as, but not limited to, those described in US91 / 09630, US91 / 05939, US94 / 01234, International Application Nos. GB89 / 01334, GB91 / 01134, GB92 / 01755, International Publication Nos. WO 90 / 14443, WO 90 / 14424, WO 90 / 14430, and European Patent No. 229246 (each of which is incorporated by reference in its entirety, including the references cited therein).
[0045] In certain embodiments, the antibody comprises an altered (e.g., mutated) Fc region. For example, in some embodiments, the Fc region is altered to reduce or enhance the effector function of the antibody. In some embodiments, the Fc region is an isotype selected from IgM, IgA, IgG, IgE, or other isotypes. Alternatively, or in addition, it may be useful to combine the amino acid modification with one or more further amino acid modifications that alter the C1q binding and / or complement dependent cytotoxicity function of the Fc region of the IL-23 binding molecule. Starting polypeptides of particular interest may be those that bind C1q and exhibit complement dependent cytotoxicity (CDC). Polypeptides with existing C1q binding activity, and optionally further with the ability to mediate CDC, may be modified to enhance one or both of these activities. Amino acid modifications that alter C1q and / or modify its complement dependent cytotoxicity function are described, for example, in WO 0042072, which is incorporated herein by reference.
[0046] As disclosed above, the Fc region of the human IL-23 specific antibody of the present invention can be engineered with altered effector functions, for example, by modifying C1q binding and / or FcγR binding, thereby altering complement-dependent cytotoxicity (CDC) activity and / or antibody-dependent cell-mediated cytotoxicity (ADCC) activity. An "effector function" serves to activate or reduce a biological activity (e.g., in a subject). Examples of effector functions include, but are not limited to, C1q binding, CDC, Fc receptor binding, ADCC, phagocytosis, downregulation of cell surface receptors (e.g., B cell receptor, BCR), and the like. Such effector functions may require the Fc region to bind to a binding domain (e.g., an antibody variable domain) and can be assessed using a variety of test methods (e.g., Fc binding assays, ADCC assays, CDC assays, and the like).
[0047] For example, a variant Fc region of a human IL-23 (or anti-IL-23) antibody can be generated that has improved C1q binding and improved FcγRIII binding (e.g., has both improved ADCC activity and improved CDC activity). Alternatively, if it is desired to reduce or eliminate effector function, the variant Fc region can be modified to have reduced CDC activity and / or to have reduced ADCC activity. In other embodiments, only one of these activities may be enhanced, optionally with the other activity reduced at the same time (e.g., to generate Fc region variants with improved ADCC activity and reduced CDC activity, and vice versa).
[0048] Fc mutations may be engineered to alter the interaction with the neonatal Fc receptor (FcRn) and improve their pharmacokinetic properties. A collection of human Fc variants with improved binding to FcRn has been described (Shields et al., (2001). High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR, J. Biol. Chem. 276:6591-6604).
[0049] Another type of amino acid substitution serves to modify the glycosylation pattern of the Fc region of a human IL-23 specific antibody. Glycosylation of the Fc region is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of one of the sugars, N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. The recognition sequences for enzymatic attachment of a carbohydrate moiety to the asparagine side chain peptide sequence are asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline. Thus, the presence of either of these peptide sequences in a polypeptide provides a potential glycosylation site.
[0050] The glycosylation pattern can be modified, for example, by deleting one or more glycosylation sites found in the polypeptide and / or adding one or more glycosylation sites not present in the polypeptide. Addition of glycosylation sites to the Fc region of a human IL-23-specific antibody is conveniently accomplished by modifying the amino acid sequence to include one or more of the tripeptide sequences listed above (for N-linked glycosylation sites). A representative glycosylation variant has an amino acid substitution of residue Asn297 of the heavy chain. This modification may also be performed by the addition of, or substitution by, one or more serine or threonine residues to the original polypeptide sequence (for O-linked glycosylation sites). In addition, changing Asn 297 to Ala can remove one of the glycosylation sites.
[0051] In certain embodiments, the human IL-23 specific antibodies of the invention are expressed in cells expressing beta(1,4)-N-acetylglucosaminyltransferase III (GnT III), such that GnT III adds GlcNAc to the human IL-23 antibody. Methods for producing antibodies in such a manner are provided in WO 99 / 54342, WO 03 / 011878, JP 2003 / 0003097(A1), and Umana et al., Nature Biotechnology, 17:176-180, Feb. 1999, all of which are expressly incorporated herein by reference in their entirety.
[0052] Anti-IL-23 antibodies can also be optionally produced by immunization of transgenic animals (e.g., mice, rats, hamsters, non-human primates, etc.) capable of producing a repertoire of human antibodies, as described herein and / or known in the art. Cells that produce human anti-IL-23 antibodies may be isolated and immortalized from such animals using suitable methods, such as those described herein.
[0053] Transgenic mice capable of producing a repertoire of human antibodies that bind to human antigens can be produced using known methods (such as, but not limited to, U.S. Pat. Nos. 5,770,428, 5,569,825, 5,545,806, 5,625,126, 5,625,825, 5,633,425, 5,661,016, and 5,789,650 issued to Lonberg et al., WO 98 / 50433 to Jakobovits et al., WO 98 / 24893 to Jakobovits et al., WO 98 / 2491 to Lonberg et al., each of which is incorporated herein by reference in its entirety). No. 884 to Lonberg et al., International Publication No. WO 97 / 13852 to Lonberg et al., International Publication No. WO 94 / 25585 to Lonberg et al., International Publication No. WO 96 / 34096 to Kucherlapate et al., European Patent No. 0463151(B1) to Kucherlapate et al., European Patent No. 0710719(A1) to Kucherlapate et al., U.S. Pat. No. 5,545,807 to Surani et al., International Publication No. WO 90 / 04036 to Bruggemann et al., European Patent No. 0438474(B1) to Bruggemann et al., European Patent No. 0814259(A2) to Lonberg et al., UK Patent No. 2272440(A) to Lonberg et al., et al.Nature 368:856-859(1994),Taylor et al.,Int.Immunol.6(4)579-591(1994),Green et al,Nature Genetics 7:13-21(1994),Mendez et al.,Nature Genetics 15:146-156(1997),Taylor et al. al., Nucleic Acids Research 20(23):6287-6295(1992), Tuaillon et al., Proc Natl Acad Sci USA 90(8)3720-3724(1993), Lonberg et al., Int Rev Immunol 13(1):65-93(1995), and Fishwald et al., Nat. Biotechnol 14(7):845-851(1996)).Generally, these mice contain at least one transgene that comprises DNA derived from at least one human immunoglobulin locus that has been functionally rearranged, or is capable of undergoing functional rearrangement. The endogenous immunoglobulin loci of such mice can be disrupted or deleted to eliminate the ability of the mice to produce antibodies encoded by endogenous genes.
[0054] Screening of antibodies for specific binding to similar proteins or fragments can be successfully accomplished using peptide display libraries. The method involves screening a large collection of peptides for individual members with the desired function or structure. Antibody screening of peptide display libraries is well known in the art. The displayed peptide sequences can be 3-5000 or more amino acids long, frequently 5-100 amino acids long, and often about 8-25 amino acids long. In addition to direct chemical synthesis methods for creating peptide libraries, several recombinant DNA methods have also been described. One type involves the display of peptide sequences on the surface of bacteriophages or cells. Each bacteriophage or cell contains a nucleotide sequence that codes for a particular displayed peptide sequence. Such methods are described in WO 91 / 17271, WO 91 / 18980, WO 91 / 19818, and WO 93 / 08278.
[0055] Other systems for generating peptide libraries include aspects of both in vitro chemical synthesis and recombinant methods. See WO 92 / 05258, WO 92 / 14843, and WO 96 / 19256. See also U.S. Patent Nos. 5,658,754 and 5,643,768. Peptide display libraries, vectors, and screening kits are commercially available from suppliers such as Invitrogen (Carlsbad, CA) and Cambridge antibody Technologies (Cambridgeshire, UK). See, e.g., U.S. Patent Nos. 4,704,692, 4,939,666, 4,946,778, 5,260,203, 5,455,030, 5,518,889, 5,534,621, 5,656,730, 5,763,733, 5,767,260, and 5,856,456 all assigned to Enzon; U.S. Patent Nos. 5,223,409, 5,403,484, 5,571,698, and 5,837,500 all assigned to Dyax; U.S. Patent Nos. 5,427,908 and 5,580,717 all assigned to Affymax; Cambridge antibody See U.S. Patent No. 5,885,793 assigned to Eppendorf Technologies, U.S. Patent No. 5,750,373 assigned to Genentech, U.S. Patent Nos. 5,618,920, 5,595,898, 5,576,195, 5,698,435, 5,693,493, 5,698,417 assigned to Xoma, Colligan, supra, Ausubel, supra, or Sambrook, supra. Each of the above patents and publications is incorporated herein by reference in its entirety.
[0056] The antibodies used in the methods of the invention can also be prepared using nucleic acids encoding at least one anti-IL23 antibody to provide transgenic animals or mammals, such as goats, cows, horses, sheep, rabbits, etc., that produce such antibodies in their milk. Such animals can be provided using known methods. See, for example, but not limited to, U.S. Patent Nos. 5,827,690, 5,849,992, 4,873,316, 5,849,992, 5,994,616, 5,565,362, 5,304,489, etc., each of which is incorporated herein by reference in its entirety.
[0057] The antibodies used in the methods of the invention can further be prepared using at least one anti-IL23 antibody encoding nucleic acid to provide transgenic plants and cultured plant cells (e.g., but not limited to, tobacco and corn) that produce such antibodies, specific portions, or variants in plant parts or cells cultured therefrom. As a non-limiting example, transgenic tobacco leaves expressing recombinant proteins, for example, using an inducible promoter, have been successfully used to provide large quantities of recombinant proteins. See, e.g., Cramer et al., Curr. Top. Microbol. Immunol. 240:95-118 (1999) and references cited therein. Transgenic corn has also been used to express mammalian proteins at commercial production levels with biological activity equivalent to proteins produced in other recombinant systems or purified from natural sources. See, e.g., Hood et al., Adv. Exp. Med. Biol. 464:127-147 (1999) and references cited therein. Antibodies have also been produced in large quantities from transgenic plant seeds containing antibody fragments, such as single chain antibodies (scFv), including tobacco seeds and potato tubers. See, e.g., Conrad et al., Plant Mol. Biol. 38:101-109 (1998) and references cited therein. Thus, the antibodies of the present invention can also be produced using transgenic plants according to known methods. See, e.g., Fischer et al., Biotechnol. Appl. Biochem. 30:99-108 (Oct., 1999); Ma et al., Trends Biotechnol. 13:522-7 (1995); Ma et al., Plant Physiol. 109:341-6 (1995); Whitelam et al., Biochem. Soc. Trans. 22:940-944 (1994); and references cited therein. Each of the above documents is incorporated herein by reference in its entirety.
[0058] The antibodies used in the methods of the present invention have a wide range of affinities (K D ) can bind human IL-23. In a preferred embodiment, the human mAb can optionally bind human IL-23 with high affinity. For example, the human mAb can bind human IL-23 at about 10 -7 M or less, for example, but not limited to, 0.1 to 9.9 (or any range or value therein) x 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 K, or any range or value therein D can be combined with
[0059] The affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method. (See, e.g., Berzofsky, et al., "Antibody-Antigen Interactions," Fundamental Immunology, Paul, WE, Ed., Raven Press: New York, NY (1984); Kuby, Janis Immunology, WH Freeman and Company: New York, NY (1992), and methods described therein.) The affinity measured for a particular antibody-antigen interaction can be different when measured under different conditions (e.g., salt concentration, pH). Thus, affinity and other antigen binding parameters (e.g., K D , K a , K d Measurements of ) are preferably performed using standardized solutions of antibody and antigen, and standardized buffers, such as those described herein.
[0060] nucleic acid molecule Using the information provided herein, e.g., a nucleotide sequence encoding at least 70-100% of the contiguous amino acids of at least one of the variable or CDR regions of the light or heavy chains described herein, specific fragments, variants, or consensus sequences thereof, or a deposited vector comprising at least one of these sequences, among others, a nucleic acid molecule of the invention encoding at least one anti-IL-23 antibody can be obtained using methods described herein or known in the art.
[0061] The nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, hnRNA, tRNA, or any other form, or in the form of DNA, including but not limited to cDNA and genomic DNA obtained by cloning or produced synthetically, or any combination thereof. The DNA may be triple-stranded, double-stranded, or single-stranded, or any combination thereof. Any portion of at least one strand of the DNA or RNA may be the coding strand, also known as the sense strand, or the non-coding strand, called the antisense strand.
[0062] The isolated nucleic acid molecules used in the methods of the present invention may include nucleic acid molecules that include an open reading frame (ORF) with at least one particular portion of at least one CDR, such as, but not limited to, at least one heavy or light chain CDR1, CDR2, and / or CDR3, optionally including one or more introns, nucleic acid molecules that include coding sequences for anti-IL-23 antibodies or variable regions, and nucleic acid molecules that include substantially different nucleotide sequences than those described above, but still encode at least one anti-IL-23 antibody described herein and / or known in the art due to the degeneracy of the genetic code. Of course, the genetic code is well known in the art. Thus, it would be routine for a person skilled in the art to generate such degenerate nucleic acid variants that encode the specific anti-IL-23 antibodies used in the methods of the present invention. See, for example, Ausubel et al., supra. Such nucleic acid variants are encompassed by the present invention. Non-limiting examples of isolated nucleic acid molecules include nucleic acids encoding HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3, respectively.
[0063] As described herein, nucleic acid molecules comprising nucleic acids encoding anti-IL-23 antibodies can include those that themselves encode the amino acid sequence of an antibody fragment, sequences encoding the full length of an antibody or a portion of an antibody, coding sequences for an antibody, fragment or portion, and additional sequences, such as at least one intron, with or without the aforementioned additional coding sequences, including, but not limited to, non-coding 5' and 3' sequences, e.g., transcribed non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals (e.g., ribosome binding and stability of mRNA), as well as additional non-coding sequences, but not limited to, coding sequences for at least one signal leader or fusion peptide, additional coding sequences encoding additional amino acids, e.g., amino acids that provide additional functions. Thus, the antibody coding sequence can be fused to a marker sequence, e.g., a marker sequence is a sequence that encodes a peptide that facilitates purification of an antibody comprising the antibody fragment or portion to which it is fused.
[0064] Polynucleotides that selectively hybridize to the polynucleotides described herein The method of the present invention uses isolated nucleic acids that hybridize under selective hybridization conditions to the polynucleotides disclosed herein. Thus, the polynucleotides of the present embodiment can be used to isolate, detect, and / or quantify nucleic acids that contain such polynucleotides. For example, the polynucleotides of the present invention can be used to identify, isolate, or amplify partial or full-length clones in a deposited library. In some embodiments, the polynucleotides are genomic or cDNA sequences that are isolated or otherwise complementary to cDNAs in a human or mammalian nucleic acid library.
[0065] Preferably, the cDNA library contains at least 80% of the full-length sequences, preferably at least 85% or 90% of the full-length sequences, more preferably at least 95% of the full-length sequences. The cDNA library can be normalized to increase the representation of rare sequences. Low or medium stringency hybridization conditions are typical, but not limited to, using sequences with low sequence identity to the complementary sequence. Optionally, medium and high stringency conditions can be used for sequences with higher identity. Low stringency conditions allow selective hybridization of sequences with about 70% sequence identity and can be used to identify orthologous or paralogous sequences.
[0066] Optionally, the polynucleotide encodes at least a portion of an antibody. The polynucleotide comprises a nucleic acid sequence that can be used for selective hybridization to a polynucleotide encoding an antibody of the present invention. See, e.g., Ausubel, supra; Colligan, supra, each of which is incorporated herein by reference in its entirety.
[0067] Nucleic acid construction An isolated nucleic acid can be produced using (a) recombinant methods, (b) synthetic techniques, (c) purification techniques, and / or (d) combinations thereof, as are well known in the art.
[0068] The nucleic acid may conveniently contain sequences in addition to the polynucleotide of the invention. For example, a multiple cloning site containing one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in the isolation of the polynucleotide. Also, a translatable sequence may be inserted to aid in the isolation of the translated polynucleotide of the invention. For example, a hexahistidine marker sequence provides a convenient means for purifying the protein of the invention. The nucleic acid of the invention (excluding the coding sequence) is optionally a vector, adapter, or linker for cloning and / or expression of the polynucleotide of the invention.
[0069] Additional sequences can be added to such cloning and / or expression sequences to optimize their function in cloning and / or expression, to aid in the isolation of polynucleotides, or to improve the introduction of polynucleotides into cells. The use of cloning vectors, expression vectors, adapters, and linkers is well known in the art. (See, e.g., Ausubel, supra, or Sambrook, supra.)
[0070] Recombinant methods for constructing nucleic acids Isolated nucleic acid compositions, such as RNA, cDNA, genomic DNA, or any combination thereof, can be obtained from biological sources using any number of cloning methods known to those of skill in the art. In some embodiments, oligonucleotide probes that selectively hybridize under stringent conditions to the polynucleotides of the present invention are used to identify desired sequences in cDNA or genomic DNA libraries. Isolation of RNA and construction of cDNA and genomic libraries are well known to those of skill in the art. (See, e.g., Ausubel, supra, or Sambrook, supra).
[0071] Nucleic Acid Screening and Isolation Methods Probes based on the sequences of the polynucleotides used in the methods of the invention, such as those disclosed herein, can be used to screen cDNA or genomic libraries. Probes can be used to hybridize to genomic DNA or cDNA sequences to isolate homologous genes in the same or different organisms. Those skilled in the art will appreciate that various degrees of hybridization stringency can be used in the assay, and either the hybridization or wash medium can be stringent. The more stringent the hybridization conditions, the greater the degree of complementarity between the probe and target at which duplex formation occurs. The degree of stringency can be controlled by one or more of temperature, ionic strength, pH, and the presence of a partially denaturing solvent, such as formamide. For example, the stringency of hybridization is successfully altered by changing the polarity of the reaction solution, for example, by manipulation of the formamide concentration in the range of 0% to 50%. The degree of complementarity (sequence identity) required for detectable binding varies depending on the stringency of the hybridization medium and / or the wash medium. The degree of complementarity is optimally 100%, or 70-100%, or any range or value therein, however, it should be understood that minor differences in sequence in the probe and primers can be compensated for by reducing the stringency of the hybridization and / or wash medium.
[0072] Methods for amplifying RNA or DNA are well known in the art and can be used in accordance with the present invention without undue experimentation, based on the teachings and guidance provided herein.
[0073] Known methods of DNA or RNA amplification include the polymerase chain reaction (PCR) and related amplification processes (e.g., U.S. Pat. Nos. 4,683,195, 4,683,202, 4,800,159, and 4,965,188 to Mullis et al., U.S. Pat. Nos. 4,795,699 and 4,921,794 to Tabor et al., U.S. Pat. No. 5,142,033 to Innis, U.S. Pat. No. 5,122,464 to Wilson et al., U.S. Pat. No. 5,091,310 to Innis, U.S. Pat. No. 5,066,584 to Gyllensten et al., U.S. Pat. No. 5,066,584 to Gelfa et al., U.S. Pat. No. 5,122,464 to Innis, U.S. Pat. No. 5,091,310 ...122 No. 4,889,818 to nd et al., U.S. Patent No. 4,994,370 to Silver et al., U.S. Patent No. 4,766,067 to Biswas, and U.S. Patent No. 4,656,134 to Ringold), and RNA-mediated amplification (U.S. Patent No. 5,130,238 to Malek et al., trade name NASBA), which uses antisense RNA to a target sequence as a template for double-stranded DNA synthesis, the entire contents of which are incorporated herein by reference. (See, e.g., Ausubel, supra, or Sambrook, supra.)
[0074] For example, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides and related genes used in the methods of the present invention directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification methods can also be useful, for example, for cloning nucleic acid sequences encoding proteins to be expressed, for generating nucleic acids to be used as probes for detecting the presence of desired mRNA in a sample, for sequencing nucleic acids, or for other purposes. Examples of techniques sufficient to guide the skilled artisan through in vitro amplification methods can be found in Berger, Sambrook, and Ausubel, supra, as well as U.S. Patent No. 4,683,202 to Mullis et al. (1987), and Innis, et al., PCR Protocols A Guide to Methods and Applications, Eds., Academic Press Inc., San Diego, CA (1990). Commercial kits for genomic PCR amplification are known in the art. See, for example, Advantage-GC Genomic PCR Kit (Clontech). In addition, for example, the T4 gene 32 protein (Boehringer Mannheim) can be used to improve yields of long PCR products.
[0075] Synthetic methods for constructing nucleic acids The isolated nucleic acid used in the method of the present invention can also be prepared by direct chemical synthesis by known methods (see, for example, Ausubel et al., supra). Chemical synthesis generally produces a single-stranded oligonucleotide that can be converted into double-stranded DNA by hybridization with a complementary sequence or by polymerization with a DNA polymerase using the single strand as a template. Those skilled in the art will recognize that chemical synthesis of DNA can be limited to sequences of about 100 or more bases, but longer sequences can be obtained by ligation of shorter sequences.
[0076] Recombinant Expression Cassettes The present invention employs recombinant expression cassettes comprising nucleic acids. Nucleic acid sequences, such as cDNA or genomic sequences encoding an antibody used in the methods of the present invention, can be used to construct recombinant expression cassettes that can be introduced into at least one desired host cell. Recombinant expression cassettes typically comprise a polynucleotide that is operably linked to a transcription initiation regulatory sequence that directs transcription of the polynucleotide in the intended host cell. Both heterologous and non-heterologous (i.e., endogenous) promoters can be utilized to direct expression of the nucleic acid.
[0077] In some embodiments, isolated nucleic acids that function as promoters, enhancers, or other elements can be introduced into a suitable location (upstream, downstream, or within an intron) of a non-heterologous form of a polynucleotide of the invention to up- or down-regulate expression of the polynucleotide. For example, endogenous promoters can be altered in vivo or in vitro by mutation, deletion, and / or substitution.
[0078] Vectors and host cells The present invention also relates to vectors containing the isolated nucleic acid molecules, host cells genetically engineered with the recombinant vectors, and the production of at least one anti-IL-23 antibody by recombinant techniques that are well known in the art (see, e.g., Sambrook et al., supra; Ausubel et al., supra, each of which is incorporated herein by reference in its entirety).
[0079] The polynucleotide can be optionally linked to a vector that contains a selection marker for propagation in the host.Generally, the plasmid vector is introduced into a precipitate such as a calcium phosphate precipitate or into a complex with a charged lipid.If the vector is a virus, it can be packaged in vitro using a suitable packaging cell line and then transduced into the host cell.
[0080] The DNA insert should be operably linked to a suitable promoter. The expression construct further comprises a transcription initiation site, a transcription termination site, and, within the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcript expressed by the construct preferably comprises translation beginning with a start and stop codon (e.g., UAA, UGA, or UAG) appropriately positioned at the end of the mRNA to be translated, with UAA and UAG being preferred for expression in mammalian or eukaryotic cells.
[0081] It is preferred, but optional, that the expression vector includes at least one selectable marker. Such markers include, for example, methotrexate (MTX), dihydrofolate reductase (DHFR, U.S. Pat. Nos. 4,399,216, 4,634,665, 4,656,134, 4,956,288, 5,149,636, and 5,179,017, ampicillin, neomycin (G418), mycophenolic acid, or glutamine synthetase for eukaryotic cell culture. synthetase, GS, U.S. Patent Nos. 5,122,464, 5,770,359, 5,827,739) resistance genes, and tetracycline or ampicillin resistance genes for culture in E. coli and other bacteria or prokaryotes (the above patents are incorporated herein by reference in their entireties). Appropriate culture media and conditions for the above host cells are known in the art. Suitable vectors will be readily apparent to those of ordinary skill in the art. Introduction of the vector construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid mediated transfection, electroporation, transduction, infection or other known methods. Such methods are described in the art, such as Sambrook, supra, Chapters 1-4 and 16-18, and Ausubel, supra, Chapters 1, 9, 13, 15, 16.
[0082] At least one antibody used in the method of the invention may be expressed in modified form, such as a fusion protein, and may contain not only secretion signals, but also additional heterologous functional regions. For example, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the antibody to improve stability and persistence in the host cell during purification or during subsequent processing and storage. Peptide moieties may also be added to the antibody of the invention to facilitate purification. Such regions may be removed prior to final preparation of the antibody or at least one fragment thereof. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, Chapters 17.29-17.42 and 18.1-18.74, Ausubel, supra, Chapters 16, 17, and 18.
[0083] Those skilled in the art are familiar with the many expression systems available for expressing the nucleic acid encoding the protein used in the method of the present invention. Alternatively, the nucleic acid can be expressed in a host cell by switching on (by manipulation) in the host cell containing the endogenous DNA encoding the antibody. Such methods are well known in the art, as described in U.S. Patent Nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761, which are incorporated herein by reference in their entirety.
[0084] An example of a cell culture useful for the production of antibodies, specified portions or variants thereof are mammalian cells. Mammalian cell lines are often in the form of a monolayer of cells, although suspensions or bioreactors of mammalian cells can also be used. A number of suitable host cell lines capable of expressing intact glycosylated proteins have been developed in the art, including COS-1 (e.g., ATCC CRL 1650), COS-7 (e.g., ATCC CRL-1651), HEK293, BHK21 (e.g., ATCC CRL-10), CHO (e.g., ATCC CRL1610) and BSC-1 (e.g., ATCC CRL-26) cell lines, Cos-7 cells, CHO cells, hep G2 cells, P3X63Ag8.653, SP2 / 0-Ag14, 293 cells, HeLa cells, and the like, which are readily available, for example, from the American Type Culture Collection (Manassas, Va.) (www.atcc.org). Preferred host cells include cells derived from lymphatic system, such as myeloma and lymphoma cells. Particularly preferred host cells are P3X63Ag8.653 cells (ATCC deposit number CRL-1580) and SP2 / 0-Ag14 cells (ATCC deposit number CRL-1851). In a particularly preferred embodiment, the recombinant cell is P3X63Ab8.653 or SP2 / 0-Ag14 cell.
[0085] Expression vectors for these cells can include one or more of the following expression control sequences, including, but not limited to, an origin of replication, a promoter (e.g., the late or early SV40 promoter, the CMV promoter (U.S. Pat. Nos. 5,168,062, 5,385,839), the HSV tk promoter, the pgk (phosphoglycerate kinase) promoter, the EF-1 alpha promoter (U.S. Pat. No. 5,266,491), at least one human immunoglobulin promoter, an enhancer, and / or processing information sites such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., the SV40 large T Ag polyaddition site), and transcription termination sequences. See, e.g., Ausubel et al., supra; Sambrook et al., supra. Other cells useful for producing the nucleic acids or proteins of the invention are known and / or can be found, for example, in the American Type Culture Collection Catalogue of Cell Lines and These are available from Hybridomas (www.atcc.org) or other known or commercial sources.
[0086] When eukaryotic host cells are used, typically polyadenylation or transcription termination sequences are incorporated into the vector. An example of a termination sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript can also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, et al., J. Virol. 45:773-781 (1983)). In addition, gene sequences for controlling replication in host cells can be incorporated into the vector, as is known in the art.
[0087] Antibody purification Anti-IL-23 antibodies can be recovered and purified from recombinant cell cultures by well-known methods, including, but not limited to, protein A purification, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. High performance liquid chromatography ("HPLC") can also be used for purification. See, for example, Colligan, Current Protocols in Immunology or Current Protocols in Protein Science, John Wiley & Sons, NY, NY (1997-2001), e.g., chapters 1, 4, 6, 8, 9, 10, each of which is incorporated herein by reference in its entirety.
[0088] Antibodies for use in the methods of the invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from eukaryotic hosts including, for example, yeast, higher plants, insect, and mammalian cells. Depending on the host utilized in a recombinant production process, the antibodies may be glycosylated or non-glycosylated, although glycosylated is preferred. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, Sections 17.37-17.42; Ausubel, supra, Chapters 10, 12, 13, 16, 18, and 20; Colligan, Protein Science, supra, Chapters 12-14, all of which are incorporated herein by reference in their entirety.
[0089] Anti-IL-23 antibody. The anti-IL-23 antibodies of the present invention comprise at least a portion of an immunoglobulin molecule, which may be incorporated into the antibody, including, but not limited to, at least one ligand binding portion (LBP), such as, but not limited to, a heavy or light chain complementarity determining region (CDR) or a ligand binding portion thereof, a heavy or light chain variable region, a framework region (e.g., FR1, FR2, FR3, FR4, or a fragment thereof, optionally including at least one substitution, insertion, or deletion), a heavy or light chain constant region (e.g., at least one CDR, FR5, FR6, FR7, FR8, FR9, FR10, FR11, FR12, FR13, FR14, FR15, FR16, FR17, FR18, FR19, FR109, FR1111, FR112, FR13, FR14, FR15, FR16, FR17, FR18, FR19 ... H 1, Hinge 1, Hinge 2, Hinge 3, Hinge 4, C H 2 or C H 3, or a fragment thereof, and optionally further comprising at least one substitution, insertion, or deletion), or any portion thereof. The antibody can include or be derived from any mammal, such as, but not limited to, human, mouse, rabbit, rat, rodent, primate, or any combination thereof.
[0090] The isolated antibodies used in the methods of the invention include the amino acid sequences of the antibodies disclosed herein encoded by any suitable polynucleotide, or any isolated or prepared antibody. Preferably, the human antibodies or antigen-binding fragments bind to human IL-23, thereby partially or substantially neutralizing at least one biological activity of the protein. Antibodies, or specified portions or variants thereof, that partially or preferably substantially neutralize at least one biological activity of at least one IL-23 protein or fragment, can bind to the protein or fragment, thereby inhibiting an activity mediated through binding of IL-23 to the IL-23 receptor, or through other IL-23-dependent or mediated mechanisms. As used herein, the term "neutralizing antibody" refers to an antibody that can inhibit IL-23-dependent activity by about 20-120%, preferably at least about 10, 20, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% or more, depending on the assay. The ability of an anti-IL-23 antibody to inhibit IL-23-dependent activity is preferably assessed by at least one suitable IL-23 protein or receptor assay described herein and / or known in the art. Human antibodies may be of any class (IgG, IgA, IgM, IgE, IgD, etc.) or isotype and may include a kappa or lambda light chain. In one embodiment, the human antibody comprises an IgG heavy chain or defined fragment, e.g., at least one of the isotypes, IgG1, IgG2, IgG3, or IgG4 (e.g., γ1, γ2, γ3, γ4). Antibodies of this type can be prepared by utilizing transgenic mice or other non-human transgenic mammals that contain at least one human light chain (e.g., IgG, IgA, and IgM) transgene as described herein and / or known in the art. In another embodiment, the anti-IL-23 human antibody comprises an IgG1 heavy chain and an IgG1 light chain.
[0091] The antibody binds to at least one particular epitope specific for at least one IL-23 protein, subunit, fragment, portion, or any combination thereof, which may comprise at least one antibody binding region that comprises at least a portion of the protein, preferably comprising at least one extracellular, soluble, hydrophilic, exoportion, or cytoplasmic portion of the protein.
[0092] Generally, a human antibody or antigen-binding fragment comprises an antigen-binding region that comprises at least one human complementarity determining region (CDR1, CDR2, and CDR3) or variant of at least one heavy chain variable region, and at least one human complementarity determining region (CDR1, CDR2, and CDR3) or variant of at least one light chain variable region. The CDR sequences can be derived from human germline sequences or can match exactly to germline sequences. For example, CDRs from a synthetic library derived from the original non-human CDRs can be used. These CDRs can be formed by incorporation of conservative substitutions from the original non-human sequence. In another specific embodiment, the antibody or antigen-binding portion or variant can have an antigen-binding region that comprises at least a portion of at least one light chain CDR (i.e., CDR1, CDR2, and / or CDR3) with the corresponding CDR1, 2, and / or 3 amino acid sequence.
[0093] Such antibodies can be prepared by preparing and expressing a nucleic acid molecule encoding the antibody (i.e., one or more) using conventional techniques involving recombinant DNA technology, or by chemically linking together the various portions of the antibody (e.g., CDRs, framework) using conventional techniques, or by using any other suitable method.
[0094] An anti-IL-23 specific antibody can comprise at least one of a heavy or light chain variable region having a defined amino acid sequence. For example, in a preferred embodiment, an anti-IL-23 antibody comprises at least one of a heavy chain variable region, optionally having the amino acid sequence of SEQ ID NO: 7, and / or at least one of a light chain variable region, optionally having the amino acid sequence of SEQ ID NO: 8. For example, in a preferred embodiment, an anti-IL-23 antibody comprises at least one of a heavy chain variable region, optionally having the amino acid sequence of SEQ ID NO: 9, and / or at least one of a light chain variable region, optionally having the amino acid sequence of SEQ ID NO: 10. Antibodies that bind to human IL-23 and comprise a defined heavy or light chain variable region can be prepared using suitable methods, such as those employing phage display (Katsube, Y., et al., Int J Mol. Med, 1(5):863-868 (1998)) or transgenic animals, as known in the art and / or described herein. For example, a transgenic mouse containing a functionally rearranged human immunoglobulin heavy chain transgene and a transgene containing DNA from a human immunoglobulin light chain locus capable of undergoing functional rearrangement can be immunized with human IL-23 or a fragment thereof to induce the production of antibodies. If desired, antibody-producing cells can be isolated and hybridomas or other immortalized antibody-producing cells can be prepared as described herein and / or known in the art. Alternatively, antibodies, particular portions or variants can be expressed using the encoding nucleic acid or a portion thereof in a suitable host cell.
[0095] The present invention also relates to antibodies, antigen-binding fragments, immunoglobulin chains and CDRs that contain amino acids in sequences that are substantially the same as the amino acid sequences described herein. Preferably, such antibodies or antigen-binding fragments and antibodies that contain such chains or CDRs have high affinity (e.g., about 10 -9 K below M D) can bind to human IL-23. Amino acid sequences that are substantially the same as the sequences described herein include sequences containing conservative amino acid substitutions as well as amino acid deletions and / or insertions. A conservative amino acid substitution refers to the replacement of a first amino acid with a second amino acid that has chemical and / or physical properties (e.g., charge, structure, polarity, hydrophobicity / hydrophilicity) similar to those of the first amino acid. Conservative substitutions include, but are not limited to, replacing one amino acid with another within the following groups: lysine (K), arginine (R), and histidine (H); aspartate (D) and glutamate (E); asparagine (N), glutamine (Q), serine (S), threonine (T), tyrosine (Y), K, R, H, D, and E; alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), tryptophan (W), methionine (M), cysteine (C), and glycine (G); F, W, and Y; C, S, and T.
[0096] Amino acid code The amino acids constituting the anti-IL-23 antibodies of the present invention are often abbreviated. Amino acid notation can be indicated by representing the amino acid by its one-letter code, its three-letter code, name, or three-nucleotide codon, and is well understood in the art (see Alberts, B. et al., Molecular Biology of The Cell, 3rd Edition, Garland Publishing, Inc., New York (1994)).
[0097] [Table 1]
[0098] The IL-23 antibodies used in the methods of the invention may contain one or more amino acid substitutions, deletions, or additions, either due to natural mutations or human manipulation, as specified herein.
[0099] The number of amino acid substitutions that one of skill in the art may make will depend on many factors, including those described above. Generally speaking, the number of amino acid substitutions, insertions, or deletions in a given anti-IL-23 antibody, fragment, or variant, as specified herein, is 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or less, e.g., 1 to 30, or any range or value therein.
[0100] Amino acids within an anti-IL-23 specific antibody that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine scanning mutagenesis (e.g., Ausubel, supra, Chapters 8, 15; Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity, including, but not limited to, at least one IL-23 neutralizing activity. Sites critical for antibody binding can also be identified by structural analysis, such as crystallization, nuclear magnetic resonance, or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992) and de Vos et al., Science 255:306-312 (1992)).
[0101] An anti-IL-23 antibody can include, but is not limited to, at least one portion, sequence, or combination selected from all five of at least one of the contiguous amino acids of SEQ ID NOs: 1, 2, 3, 4, 5, and 6.
[0102] The IL-23 antibody or specific portion or variant may include, but is not limited to, at least one portion, sequence, or combination selected from at least 3 to 5 contiguous amino acids of the above SEQ ID NO:, 5 to 17 contiguous amino acids of the above SEQ ID NO:, 5 to 10 contiguous amino acids of the above SEQ ID NO:, 5 to 11 contiguous amino acids of the above SEQ ID NO:, 5 to 7 contiguous amino acids of the above SEQ ID NO:, or 5 to 9 contiguous amino acids of the above SEQ ID NO:.
[0103] The IL-23 antibody can further optionally comprise at least one polypeptide that is 70-100% of 5, 17, 10, 11, 7, 9, 119, or 108 contiguous amino acids of SEQ ID NO: above. In one embodiment, the amino acid sequence of an immunoglobulin chain or portion thereof (e.g., variable region, CDR) has about 70-100% identity (e.g., 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or any range or value therein) with the amino acid sequence of at least one corresponding chain of SEQ ID NO: above. For example, the amino acid sequence of the light chain variable region can be compared to the sequence of SEQ ID NO: above, or the amino acid sequence of the heavy chain CDR3 can be compared to the sequence of SEQ ID NO: above. Preferably, 70-100% amino acid identity (i.e., 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or any range or value therein) is determined using a suitable computer algorithm known in the art.
[0104] "Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including, but not limited to, those described in Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., Siam J. Applied Math., 48:1073 (1988). Additionally, percent identity values can be obtained from amino acid and nucleotide sequence alignments generated using default settings in AlignX, a component of Vector NTI Suite 8.0 (Informax, Frederick, MD).
[0105] Preferred methods for determining identity are designed to obtain the highest degree of correspondence between the sequences tested. Methods for determining identity and similarity are codified in publicly available computer programs. Preferred computer program methods for determining identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J. et al., Nucleic Acids Research 12(1):387(1984)), BLASTP, BLASTN, and FASTA (Atschul, SF et al., J. Molec. Biol. 215:403-410(1990)). BLAST X programs are publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCBINLM NIH Bethesda, Md. 20894: Altschul, S. et al., J. Mol. Biol. 215:403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.
[0106] Preferred parameters for polypeptide sequence comparison include the following: (1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48:443-453 (1970) Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci, USA. 89:10915-10919 (1992); Gap penalty: 12 Gap length penalty: 4 A program useful with these parameters is publicly available as the "Gap" program from the Genetics Computer Group, Madison Wis. The aforementioned parameters are the default parameters for peptide sequence comparisons (as well as no penalty for end gaps).
[0107] Preferred parameters for polynucleotide comparisons include the following: (1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970) Comparison matrix: match = +10, mismatch = 0 Gap penalty: 50 Gap length penalty: 3 Available as the "Gap" program from the Genetics Computer Group, Madison Wis. These are the default parameters for nucleic acid sequence comparisons.
[0108] As an example, a polynucleotide sequence may be identical to another sequence, i.e., 100% identical, or may contain up to a certain integer number of nucleotide alterations compared to a reference sequence. Such alterations are selected from the group consisting of deletion, substitution (including transitions and transversions), or insertion of at least one nucleotide, which may occur at the 5' or 3' terminal position of the reference nucleotide sequence, or anywhere between these terminal positions, and may be distributed either individually among nucleotides of the reference sequence, or in one or more adjacent groups within the reference sequence. The number of nucleotide alterations may be determined by multiplying the total number of nucleotides in the sequence by the numerical percent of the corresponding percent identity (divided by 100) and subtracting the product from the total number of nucleotides in the sequence, or is determined by n.sub.n.ltorsim.x.sub.n-(x.sub.ny), where n.sub.n is the number of nucleotide alterations, x.sub.n is the total number of nucleotides in the sequence, and y is, for example, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and any non-integer product of x.sub.n and y is rounded down to the nearest integer before subtraction from x.sub.n.
[0109] Modifications of the polynucleotide sequence encoding the above SEQ ID NOs may result in nonsense, missense, or frameshift mutations in the coding sequence, thereby modifying the polypeptide encoded by the polynucleotide after such modification. Similarly, the polypeptide sequence may be identical, i.e., 100% identical, to the reference sequence of the above SEQ ID NOs, or may contain up to a certain integer number of amino acid modifications compared to the reference sequence such that the percent identity is less than 100%. Such modifications are selected from the group consisting of deletion, substitution (including conservative and non-conservative substitutions), or insertion of at least one amino acid, which may occur at the amino or carboxy terminal position of the reference polypeptide sequence or anywhere between these terminal positions, and may be distributed either individually between the amino acids of the reference sequence, or in one or more adjacent groups within the reference sequence. The number of amino acid changes for a given percent identity may be calculated by multiplying the total number of amino acids in the above SEQ ID NOs by the numerical percent of the respective percent identity (divided by 100) and subtracting the product from the total number of amino acids in the above SEQ ID NOs, or is determined by n.sub.a.ltorsim.x.sub.a-(x.sub.ay), where n.sub.a is the number of amino acid changes, x.sub.a is the total number of amino acids in the sequence ID, and y is, for example, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, etc., and any non-integer product of x.sub.a and y is rounded down to the nearest integer before subtraction from x.sub.a.
[0110] Exemplary heavy and light chain variable region sequences, and portions thereof, are set forth in the SEQ ID NOs. An antibody of the invention, or a particular variant thereof, can include any number of contiguous amino acid residues from an antibody of the invention, the number being selected from the group of integers consisting of 10-100% of the number of contiguous residues in an anti-IL-23 antibody. Optionally, this subsequence of contiguous amino acids is at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, or more amino acids in length, or any range or value therein. Additionally, the number of such subsequences can be any integer selected from the group consisting of 1-20, such as at least 2, 3, 4, or 5.
[0111] As will be appreciated by those of skill in the art, the present invention includes at least one biologically active antibody of the present invention. A biologically active antibody has a specific activity that is at least 20%, 30%, or 40%, preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% to 100% or more (including but not limited to up to 10-fold the specific activity) of that of a natural (non-synthetic), endogenous, or related and known antibody. Methods for assaying and quantitatively measuring enzymatic activity and substrate specificity are well known to those of skill in the art.
[0112] In another aspect, the invention relates to human antibodies and antigen-binding fragments described herein that are modified by the covalent attachment of an organic moiety. Such modifications can produce antibodies or antigen-binding fragments with improved pharmacokinetic properties (e.g., increased serum half-life in vivo). The organic moiety can be a linear or branched hydrophilic polymer group, a fatty acid group, or a fatty acid ester group. In certain embodiments, the hydrophilic polymer group has a molecular weight of about 800 to about 120,000 daltons and can be a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)), a carbohydrate polymer, an amino acid polymer, or polyvinylpyrrolidone, and the fatty acid group or fatty acid ester group can contain about 8 to about 40 carbon atoms.
[0113] The modified antibodies and antigen-binding fragments can include one or more organic moieties that are directly or indirectly covalently attached to the antibody. Each organic moiety attached to the antibody or antigen-binding fragment of the present invention can be independently a hydrophilic polymer group, a fatty acid group, or a fatty acid ester group. As used herein, the term "fatty acid" includes monocarboxylic and dicarboxylic acids. As used herein, the term "hydrophilic polymer group" refers to an organic polymer that is more soluble in water than octane. For example, polylysine is more soluble in water than octane. Thus, antibodies modified by the covalent attachment of polylysine are encompassed by the present invention. Hydrophilic polymers suitable for modifying the antibodies of the present invention may be linear or branched, and include, for example, polyalkane glycols (e.g., PEG, monomethoxy-polyethylene glycol (mPEG), PPG, etc.), carbohydrates (e.g., dextran, cellulose, oligosaccharides, polysaccharides, etc.), polymers of hydrophilic amino acids (e.g., polylysine, polyarginine, polyaspartic acid, etc.), polyalkane oxides (e.g., polyethylene oxide, polypropylene oxide, etc.), and polyvinylpyrrolidone. Preferably, the hydrophilic polymers that modify the antibodies of the present invention have a molecular weight of about 800 to about 150,000 daltons as individual molecular entities. For example, PEG 5000 and PEG 20,000 can be used, where the subscript is the average molecular weight of the polymer in Daltons. The hydrophilic polymer group can be substituted with 1 to about 6 alkyl groups, fatty acid groups, or fatty acid ester groups. Hydrophilic polymers substituted with fatty acid or fatty acid ester groups can be prepared by utilizing a suitable method. For example, a polymer containing an amine group can be linked to a carboxylate of a fatty acid or fatty acid ester, and an activated carboxylate on the fatty acid or fatty acid ester (e.g., activated with N,N-carbonyldiimidazole) can be linked to a hydroxyl group on the polymer.
[0114] Fatty acids and fatty acid esters suitable for modifying antibodies of the invention may be saturated or may contain one or more units of unsaturation. Fatty acids suitable for modifying antibodies of the invention include, for example, n-dodecanoate (C 12 , laurate), n-tetradecanoate (C 14 , myristate), n-octadecanoate (C 18 , stearate), n-eicosanoate (C 20 , arachidate), n-docosanoate (C 22 , behenic acid), n-triacontanoate (C 30 ), n-tetracontanoate (C 40 ), cis-Δ9-octadecanoate (C 18 oleate), all cis-Δ5,8,11,14-eicosatetraenoate (C 20 , arachidonate), octanedioic acid, tetradecanedioic acid, octadecanedioic acid, docosanedioic acid, and the like. Suitable fatty acid esters include monoesters of dicarboxylic acids containing a straight or branched chain lower alkyl group. The lower alkyl group can contain from 1 to about 12, preferably from 1 to about 6, carbon atoms.
[0115] Modified human antibodies and antigen-binding fragments can be prepared using suitable methods, such as by reacting with one or more modifying agents. As used herein, the term "modifying agent" refers to a suitable organic group (e.g., hydrophilic polymer, fatty acid, fatty acid ester) that contains an activating group. An "activating group" is a chemical moiety or functional group that can react with a second chemical group under appropriate conditions, thereby forming a covalent bond between the modifying agent and the second chemical group. For example, amine-reactive activating groups include electrophilic groups such as tosylate, mesylate, halo (chloro, bromo, fluoro, iodo), N-hydroxysuccinimidyl esters (NHS), and the like. Activating groups that can react with thiols include, for example, maleimide, iodoacetyl, acrylolyl, pyridyl disulfide, 5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like. Aldehyde functional groups can be linked to amine- or hydrazide-containing molecules, and azide groups can react with trivalent phosphorus groups to form phosphoramidate or phosphorimide bonds. Suitable methods for introducing activating groups into molecules are known in the art (see, for example, Hermanson, GT, Bioconjugate Techniques, Academic Press: San Diego, CA (1996)). Activating groups can be attached directly to organic groups (e.g., hydrophilic polymers, fatty acids, fatty acid esters) or to linker moieties, such as divalent C 1 ~C 12 The linker moiety can be, for example, tetraethylene glycol, -(CH 2 ) 3 -, -NH-(CH 2 ) 6 -NH-, -(CH 2 ) 2 -NH- and -CH 2 -O-CH 2 -CH 2 -O-CH 2 -CH 2-O-CH-NH-. Modifiers containing a linker moiety can be produced, for example, by reacting mono-Boc-alkyldiamines (e.g., mono-Boc-ethylenediamine, mono-Boc-diaminohexane) with fatty acids in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to form amide bonds between the free amine and the fatty acid carboxylate. The Boc protecting group can be removed from the product by treatment with trifluoroacetic acid (TFA) to expose a primary amine that can be linked to another carboxylate as described, or it can be reacted with maleic anhydride and the resulting product cyclized to produce an activated maleimide derivative of the fatty acid. (See, for example, WO 92 / 16221 (Thompson et al.), the entire teachings of which are incorporated herein by reference).
[0116] Modified antibodies can be produced by reacting a human antibody or antigen-binding fragment with a modifying agent. For example, an organic moiety can be attached to the antibody in a non-site-specific manner using an amine-reactive modifying agent, e.g., an NHS ester of PEG. Modified human antibodies or antigen-binding fragments can also be prepared by reducing disulfide bonds (e.g., intrachain disulfide bonds) of an antibody or antigen-binding fragment. The reduced antibody or antigen-binding fragment can then be reacted with a thiol-reactive modifying agent to produce the modified antibody of the invention. Modified human antibodies and antigen-binding fragments containing organic moieties attached to specific sites of the antibodies of the invention can be prepared using suitable methods, such as reverse proteolysis (Fisch et al., Bioconjugate Chem., 3:147-153 (1992); Werlen et al., Bioconjugate Chem., 5:411-417 (1994); Kumaran et al., Protein Sci. 6(10):2233-2241 (1997); Itoh et al., Bioorg. Chem., 24(no. 1):59-68 (1996); Capellas et al., Biotechnol. Bioeng., 56(4):456-463 (1997)), and methods described in Hermanson, GT, Bioconjugate Techniques, Academic Press: San Diego, CA (1996).
[0117] The methods of the invention also employ IL-23 antibody compositions comprising at least one, at least two, at least three, at least four, at least five, at least six, or more of the anti-IL-23 antibodies described herein and / or known in the art, provided in a non-naturally occurring composition, mixture, or form. Such compositions include non-naturally occurring compositions comprising at least one or two full-length, C- and / or N-terminal deletion mutants, domains, fragments, or specific variants of an anti-IL-23 antibody amino acid sequence selected from the group consisting of 70-100% of the contiguous amino acids of the SEQ ID NOs. above, or specific fragments, domains, or variants thereof. A preferred anti-IL-23 antibody composition comprises at least one or two full-length, fragments, domains, or variants as at least one CDR- or LBP-containing portion of an anti-IL-23 antibody sequence described herein, e.g., 70-100% of the SEQ ID NOs. above, or specific fragments, domains, or variants thereof. More preferred compositions comprise, for example, 70-100% of at least one of the above SEQ ID NOs, or specific fragments, domains, or variants thereof, 40-99%. Such composition percentages may be by weight, volume, concentration, molarity, or molar concentration as a liquid or dry solution, mixture, suspension, emulsion, particle, powder, or colloid, as known in the art or as described herein.
[0118] Antibody compositions containing further therapeutically active ingredients The antibody compositions used in the methods of the invention can optionally further comprise an effective amount of at least one compound or protein selected from at least one of anti-infective agents, cardiovascular (CV) agents, central nervous system (CNS) agents, autonomic nervous system (ANS) agents, respiratory agents, gastrointestinal (GI) tract agents, hormonal agents, fluid or electrolyte balancing agents, hemodynamic agents, antineoplastic agents, immunomodulatory agents, ophthalmic, otic or nasal agents, topical agents, nutritional agents, etc. Such drugs are well known in the art, including the formulations, indications, dosages, and administration of each as provided herein (see, e.g., Nursing 2001 Handbook of Drugs, 21st Edition, each of which is incorporated herein by reference in its entirety). st edition, Springhouse Corp., Springhouse, PA, 2001; Health Professional's Drug Guide 2001, ed., Shannon, Wilson, Stang, Prentice-Hall, Inc., Upper Saddle River, NJ; Pharmacotherapy Handbook, Wells et al., Appleton & Lange, Stamford, CT).
[0119] As examples of drugs that can be combined with the antibodies of the method of the present invention, the anti-infective drug can be at least one selected from amebicide or at least one antiprotozoal drug, anthelmintic drug, antifungal drug, antimalarial drug, antituberculous drug or at least one antilepromatous drug, aminoglycoside, penicillin, cephalosporin, tetracycline, sulfonamide, fluoroquinolone, antiviral drug, macrolide anti-infective drug, and miscellaneous anti-infective drugs. The hormonal drug can be at least one selected from corticosteroid, androgen, or at least one anabolic steroid, estrogen, or at least one progestin, gonadotropin, antidiabetic drug, or at least one glucagon, thyroid hormone, thyroid hormone antagonist, pituitary hormone, and parathyroid mimetic drug. The at least one cephalosporin can be at least one selected from cefaclor, cefadroxil, cefazolin sodium, cefdinir, cefepime hydrochloride, cefixime, cefmetazole sodium, cefonicid sodium, cefoperazone sodium, cefotaxime sodium, cefotetan disodium, cefoxitin sodium, cefpodoxime proxetil, cefprozil, ceftazidime, ceftibuten, ceftizoxime sodium, ceftriaxone sodium, cefuroxime axetil, cefuroxime sodium, cephalexin hydrochloride, cephalexin monohydrate, cephradine, and loracarbef.
[0120] The at least one corticosteroid can be at least one selected from betamethasone, betamethasone acetate or betamethasone sodium phosphate, betamethasone sodium phosphate, cortisone acetate, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, fludrocortisone acetate, hydrocortisone, hydrocortisone acetate, hydrocortisone cypionate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone tebutate, prednisone, triamcinolone, triamcinolone acetonide, and triamcinolone diacetate. The at least one androgenic or anabolic steroid can be at least one selected from danazol, fluoxymesterone, methyltestosterone, nandrolone decanoate, nandrolone phenpropionate, testosterone, testosterone cypionate, testosterone enanthate, testosterone propionate, and a testosterone transdermal system.
[0121] The at least one immunosuppressant may be at least one selected from azathioprine, basiliximab, cyclosporine, daclizumab, lymphocyte immunoglobulin, muromonab-CD3, mycophenolate mofetil, mycophenolate mofetil hydrochloride, sirolimus, and tacrolimus.
[0122] The at least one topical anti-infective may be at least one selected from acyclovir, amphotericin B, azelaic acid cream, bacitracin, butoconazole nitrate, clindamycin phosphate, clotrimazole, econazole nitrate, erythromycin, gentamicin sulfate, ketoconazole, mafenide acetate, metronidazole (topical), miconazole nitrate, mupirocin, naftifine hydrochloride, neomycin sulfate, nitrofurazone, nystatin, silver sulfadiazine, terbinafine hydrochloride, terconazole, tetracycline hydrochloride, tioconazole, and tolnaftate. The at least one scabicide or pediculicide may be at least one selected from crotamiton, lindane, permethrin, and pyrethrins. The at least one topical corticosteroid can be at least one selected from betamethasone dipropionate, betamethasone valerate, clobetasol propionate, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, diflorasone diacetate, fluocinolone acetonide, fluocinonide, flurandrenolide, fluticasone propionate, halcionide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone valerate, mometasone furoate, and triamcinolone acetonide. (See, e.g., pages 1098-1136 of Nursing 2001 Drug Handbook.)
[0123] Anti-IL-23 antibody compositions comprise at least one anti-IL-23 antibody that is contacted or administered to a cell, tissue, organ, animal, or subject in need of such modulation, treatment, or therapy, and optionally further comprise at least one TNF antagonist (such as, but not limited to, a TNF chemical or protein antagonist, a TNF monoclonal or polyclonal antibody or fragment, a soluble TNF receptor (e.g., p55, p70, or p85) or fragment, a fusion polypeptide thereof, or a small molecule TNF antagonist, such as TNF binding protein I or II (TBP-1 or TBP-II), nerelimonmab, infliximab, The composition may further include at least one of any suitable and effective amount of compositions or pharmaceutical compositions containing at least one selected from the group consisting of antirheumatic drugs (e.g., methotrexate, auranofin, aurothioglucose, azathioprine, etanercept, sodium aurothiomalate, hydroxychloroquine sulfate, leflunomide, sulfasalazine), immunizing agents, immunoglobulins, immunosuppressants (e.g., azathioprine, basiliximab, cyclosporine, daclizumab), cytokines, or cytokine antagonists. Non-limiting examples of such cytokines include, but are not limited to, any of IL-1 to IL-40 (e.g., IL-1, IL-2, etc.). Suitable dosages are well known in the art. For example, see Wells et al., eds., Pharmacotherapy Handbook, 2 nd Edition, Appleton and Lange, Stamford, CT (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, CA (2000), each of which is incorporated herein by reference in its entirety.
[0124] The anti-IL-23 antibody compound, composition, or mixture used in the method of the present invention may further comprise at least one of any suitable auxiliary agent, such as, but not limited to, a diluent, a binder, a stabilizer, a buffer, a salt, a lipophilic solvent, a preservative, an adjuvant, etc. Pharmaceutically acceptable auxiliary agents are preferred. Non-limiting examples of methods for preparing such sterile solutions are well known in the art and are described, for example, in Gennaro, Ed., Remington's Pharmaceutical Sciences, 1896; th Edition, Mack Publishing Co. (Easton, PA) 1990. Pharmaceutically acceptable carriers suitable for the mode of administration, solubility, and / or stability of the anti-IL-23 antibody, fragment, or variant compositions well known in the art or described herein can be routinely selected.
[0125] Pharmaceutical excipients and additives useful in the present compositions include, but are not limited to, proteins, peptides, amino acids, lipids, and carbohydrates (e.g., saccharides including monosaccharides, disaccharides, trisaccharides, tetrasaccharides, and oligosaccharides, derivatized sugars such as alditols, aldonic acids, esterified sugars, and polysaccharides or sugar polymers), which may be present alone or in combination and comprise 1-99.99% by weight or volume, alone or in combination. Exemplary protein excipients include serum albumins such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, casein, and the like. Exemplary amino acids / antibody components that may also function in a buffering capacity include alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, and the like. One preferred amino acid is glycine.
[0126] Carbohydrate excipients suitable for use in the present invention include, for example, monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, etc., disaccharides such as lactose, sucrose, trehalose, cellobiose, etc., polysaccharides such as raffinose, melezitose, maltodextrin, dextran, starches, etc., alditols such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol), myo-inositol, etc. Preferred carbohydrate additives for use in the present invention are mannitol, trehalose, and raffinose.
[0127] The anti-IL-23 antibody composition may also include a buffer or pH adjusting agent, typically a salt prepared from an organic acid or base. Representative buffers include organic acid salts such as salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid, Tris, tromethamine hydrochloride, or phosphate buffers. A preferred buffer for use in the composition is an organic acid salt such as citric acid.
[0128] Additionally, anti-IL-23 antibody compositions may include polymeric excipients / additives such as polyvinylpyrrolidone, Ficoll (a polymeric sugar), dextrates (e.g., cyclodextrins such as 2-hydroxypropyl-β-cyclodextrin), polyethylene glycol, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, surfactants (e.g., polysorbates such as "TWEEN 20" and "TWEEN 80"), lipids (e.g., phospholipids, fatty acids), steroids (e.g., cholesterol), and chelating agents (e.g., EDTA).
[0129] These and additional known pharmaceutical excipients and / or additives suitable for use in the anti-IL-23 antibody, portion or variant compositions according to the invention are known in the art and are described, for example, in "Remington: The Science & Practice of Pharmacy," 1999. thed., Williams & Williams, (1995), and “Physician's Desk Reference,” 52 nd ed., Medical Economics, Montvale, NJ (1998), the disclosures of which are incorporated herein by reference in their entireties. Preferred carrier or excipient materials are carbohydrates (e.g., monosaccharides and alditols) and buffers (e.g., citric acid) or polymeric agents. Exemplary carrier molecules are mucopolysaccharides, hyaluronic acid, which may be useful for intra-articular delivery.
[0130] formulation As mentioned above, the present invention provides stable formulations, preferably saline or phosphate buffer with selected salts, as well as preservative-containing preservative solutions and formulations, and versatile preservative formulations suitable for pharmaceutical or veterinary use comprising at least one anti-IL-23 antibody in a pharma- ceutically acceptable formulation. The preservative formulations include at least one known preservative, optionally selected from the group consisting of at least one phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrate, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride (e.g., hexahydrate), alkyl parabens (methyl, ethyl, propyl, butyl, etc.), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal, or mixtures thereof, in an aqueous diluent. As known in the art, the range may be from 0.001 to 5%, or any range or value therein, for example, 0.001, 0.003, 0.005, 0.009, 0.01, 0.02, 0.03, 0.05, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 3.1, 3.2, 3.3, 3.4, 3.5, 3.7, 3.8, 3.9, 3.1, 3.2 ...3, 3.4, 3.5, 3.8, 3.9, 3.1, 3.2, 3.3, 3.4, 3.5, Any suitable concentration or mixture may be used, such as 0.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.3, 4.5, 4.6, 4.7, 4.8, 4.9, etc., or any range or value therein.Non-limiting examples include no preservatives, 0.1-2% m-cresol (e.g., 0.2, 0.3, 0.4, 0.5, 0.9, 1.0%), 0.1-3% benzyl alcohol (e.g., 0.5, 0.9, 1.1, 1.5, 1.9, 2.0, 2.5%), 0.001-0.5% thimerosal (e.g., 0.005, 0.01), 0.001-2.0% phenol (e.g., Examples of suitable alkylparabens include 0.05, 0.25, 0.28, 0.5, 0.9, 1.0%), 0.0005 to 1.0% alkylparaben (for example, 0.00075, 0.0009, 0.001, 0.002, 0.005, 0.0075, 0.009, 0.01, 0.02, 0.05, 0.075, 0.09, 0.1, 0.2, 0.3, 0.5, 0.75, 0.9, 1.0%), and the like.
[0131] As discussed above, the methods of the invention employ articles of manufacture comprising packaging and at least one vial containing a solution of at least one anti-IL-23 specific antibody, optionally with a buffer and / or preservative formulated in an aqueous diluent, the packaging comprising a label indicating that such solution can be maintained for 1, 2, 3, 4, 5, 6, 9, 12, 18, 20, 24, 30, 36, 40, 48, 54, 60, 66, 72 hours or more. The invention further employs articles of manufacture comprising packaging and a first vial containing a lyophilized anti-IL-23 specific antibody and a second vial containing an aqueous diluent of the formulated buffer or preservative, the packaging comprising a label instructing a patient to reconstitute the anti-IL-23 specific antibody with the aqueous diluent to form a solution that can be maintained for 24 hours or more.
[0132] The anti-IL-23 specific antibodies used in accordance with the present invention may be produced by recombinant means, including production from mammalian cells or transgenic preparations, or may be purified from other biological sources, as described herein or known in the art.
[0133] Ranges of anti-IL-23 specific antibodies include those amounts that will give a concentration of about 1.0 μg / ml to about 1000 mg / ml upon reconstitution for wet / dry systems, although lower and higher concentrations are workable and depend on the intended delivery vehicle, e.g., for solution formulations, as opposed to transdermal patch, pulmonary, transmucosal, or osmotic or micropump methods.
[0134] Preferably, the aqueous diluent further comprises a pharma- ceutically acceptable preservative, optionally. Preferred preservatives include those selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkyl parabens (methyl, ethyl, propyl, butyl, etc.), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal, or mixtures thereof. The concentration of the preservative used in the formulation is sufficient to produce an antimicrobial effect. Such concentration will vary depending on the preservative selected, and can be easily determined by those skilled in the art.
[0135] Other excipients, such as isotonicity agents, buffers, antioxidants, and preservative enhancers, can be optionally and preferably added to the diluent. An isotonicity agent, such as glycerin, is generally used at a known concentration. A physiologically tolerable buffer is preferably added to provide improved pH control. The formulations can cover a wide range of pH, such as from about pH 4 to about pH 10, and preferably from about pH 5 to about pH 9, and most preferably from about 6.0 to about 8.0. Preferably, the formulations of the present invention have a pH of about 6.8 to about 7.8. Suitable buffers include phosphate buffers, most preferably sodium phosphate, especially phosphate buffered saline (PBS).
[0136] Other additives, such as pharma- ceutically acceptable solubilizers, such as Tween 20 (polyoxyethylene (20) sorbitan monolaurate), Tween 40 (polyoxyethylene (20) sorbitan monopalmitate), Tween 80 (polyoxyethylene (20) sorbitan monooleate), Pluronic F68 (polyoxyethylene polyoxypropylene block copolymer), and PEG (polyethylene glycol), or non-ionic surfactants, such as polysorbate 20 or 80 or poloxamer 184 or 188, Pluronic® polyl, other block copolymers, and chelating agents, such as EDTA and EGTA, can be optionally added to the formulation or composition to reduce aggregation. These additives are particularly useful when pumps or plastic containers are used to administer the formulation. The presence of pharma-ceutically acceptable surfactants reduces the tendency of proteins to aggregate.
[0137] The formulations can be prepared by a process that includes mixing at least one anti-IL-23 antibody with a preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkyl parabens (methyl, ethyl, propyl, butyl, etc.), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal, or mixtures thereof, in an aqueous diluent. Mixing at least one anti-IL-23 specific antibody with a preservative in an aqueous diluent is performed using conventional dissolution and mixing procedures. To prepare a suitable formulation, for example, a quantity of at least one anti-IL-23 specific antibody in a buffer solution is combined with a desired preservative in a sufficient amount of buffer solution to provide the desired concentration of protein and preservative. Variations of this process will be recognized by those skilled in the art. For example, the order of addition of the components, the use or non-use of additional additives, the temperature and pH during preparation of the formulation are all factors that can be optimized for the administration concentration and administration means used.
[0138] The formulations can be provided to patients as clear solutions or as dual vials containing a vial of lyophilized anti-IL-23 specific antibody reconstituted with a second vial containing water, preservatives and / or excipients, preferably phosphate buffer and / or saline, and the selected salt in an aqueous diluent. Either the single solution vial or the dual vial requiring reconstitution can be reused multiple times to satisfy single or multiple patient treatment cycles, thus providing a more convenient treatment regimen than is currently available.
[0139] The product is useful for administration over a period ranging from immediate to 24 hours or more. Thus, the products claimed by the present invention provide significant benefits to patients. The formulations of the present invention can optionally be safely stored at temperatures between about 2° C. and about 40° C. and retain the biological activity of the protein for extended periods of time, and thus the packaging label can state that the solution can be stored and / or used for 6, 12, 18, 24, 36, 48, 72, or 96 hours or more. When using a preserved diluent, such label can include use up to 1-12 months, half a year, one and a half years, and / or up to two years.
[0140] A solution of anti-IL-23 specific antibody can be prepared by a process that includes mixing at least one antibody in an aqueous diluent. The mixing is carried out using conventional dissolution and mixing procedures. To prepare a suitable diluent, for example, a certain amount of at least one antibody in water or a buffer is combined in an amount sufficient to provide the desired concentration of protein, and optionally a preservative or buffer. Variations of this process will be recognized by those skilled in the art. For example, the order of addition of the components, whether or not additional additives are used, the temperature and pH at which the formulation is prepared are all factors that can be optimized for the administration concentration and administration means used.
[0141] The claimed products can be provided to patients as clear solutions or as combination vials containing a vial of at least one lyophilized anti-IL-23 specific antibody that is reconstituted with a second vial containing an aqueous diluent. Either the single solution vial or the dual vial requiring reconstitution can be reused multiple times to satisfy single or multiple patient treatment cycles, thus providing a more convenient treatment regimen than is currently available.
[0142] The claimed products can be provided indirectly to patients by providing a pharmacy, clinic, or other such institution or facility with a combination vial containing a clear solution or a vial of at least one lyophilized anti-IL-23 specific antibody reconstituted with a second vial containing an aqueous diluent, where the clear solution can be up to a liter or even more in volume, from which smaller amounts of the at least one antibody solution can be removed one or more times from the larger container and transferred to smaller vials and provided to customers and / or patients by the pharmacy or clinic.
[0143] Approved devices that include single vial systems include pen-type injection devices for delivering solutions, such as BD Pens, BD Autojector®, Humaject®, NovoPen®, B-DPen®, AutoPen®, and OptiPen®, GenotropinPen®, Genotronorm Pen®, Humatro Pen®, Reco-Pen®, Roferon Pen®, Biojector®, Iject®, J-tip Needle-Free Injector®, Intraject®, Medi-Ject®, Smartject®, and the like (Becton Dickensen (Franklin Suitable devices include those manufactured or developed by National Medical Products, Weston Medical (Peterborough, UK, www.weston-medical.com), Medi-Ject Corp (Minneapolis, MN, www.mediject.com), and similar suitable devices. Recognized devices that include dual vial systems include pen-type syringe systems, such as the HumatroPen®, for reconstituting lyophilized medications in a cartridge to deliver the reconstituted solution. Examples of suitable other devices include pre-filled syringes, auto-injectors, needleless syringes, and needleless IV infusion sets.
[0144] The product may include packaging. The packaging provides the conditions under which the product may be used, as well as any information required by regulatory agencies. The packaging of the present invention, when applicable, provides instructions to the patient to reconstitute at least one anti-IL-23 antibody with an aqueous diluent to form a solution and use the solution for a period of 2-24 hours or more in a wet / dry two vial product. In the case of a single vial solution product, pre-filled syringe, or autoinjector, the label indicates that such solution may be used for a period of 2-24 hours or more. The product is useful for human pharmaceutical product applications.
[0145] The formulations used in the methods of the present invention can be prepared by a process that includes mixing an anti-IL-23 antibody and a selected buffer, preferably saline or a phosphate buffer containing a selected salt. Mixing the anti-IL-23 antibody and the buffer in an aqueous diluent is performed using conventional dissolution and mixing procedures. To prepare a suitable formulation, for example, a quantity of at least one antibody in water or buffer is combined with a desired buffer in a sufficient amount of water to provide the desired concentration of protein and buffer. Variations of this process will be recognized by those skilled in the art. For example, the order of addition of the components, whether or not additional additives are used, the temperature and pH at which the formulation is prepared are all factors that can be optimized for the administration concentration and administration means used.
[0146] The method of the present invention provides pharmaceutical compositions including various formulations that are useful and acceptable for administration to human or animal patients. Such pharmaceutical compositions are prepared using "standard" water as a diluent and routine methods well known to those skilled in the art. For example, buffer components such as histidine and histidine monohydrochloride hydrate may be provided first, followed by the addition of an appropriate non-final volume of "standard" water diluent, sucrose, and polysorbate 80. The isolated antibody may then be added. Finally, the volume of the pharmaceutical composition is adjusted to the desired final volume under "standard" conditions using water as a diluent. Those skilled in the art will recognize several other methods suitable for the preparation of pharmaceutical compositions.
[0147] A pharmaceutical composition may be an aqueous solution or suspension containing the indicated mass of each component per volume unit of water or having the indicated pH at "standard conditions". As used herein, the term "standard conditions" refers to a temperature of 25°C ± 2°C and a pressure of 1 atmosphere. The term "standard conditions" is not used in the art to refer to a single set of temperatures or pressures recognized in the art, but is instead a reference condition that designates the temperature and pressure used to describe a solution or suspension containing a particular composition under the reference "standard conditions" conditions. This is because the volume of a solution is, in part, a function of temperature and pressure. Those skilled in the art will recognize that pharmaceutical compositions equivalent to those disclosed herein can be produced at other temperatures and pressures. The equivalence of such pharmaceutical compositions to those disclosed herein should be determined under the "standard conditions" conditions defined above (e.g., 25°C ± 2°C and a pressure of 1 atmosphere).
[0148] Importantly, such a pharmaceutical composition may contain "about" a certain value of the mass of a component (e.g., "about 0.53 mg of L-histidine") or have a certain value of the pH value per unit volume of the pharmaceutical composition. The mass or pH value of a component present in the pharmaceutical composition is "about" a given numerical value when the isolated antibody present in the pharmaceutical composition can bind to a peptide chain while the isolated antibody is present in the pharmaceutical composition or after the isolated antibody is removed from the pharmaceutical composition (e.g., by dilution). That is, the mass value or pH value or other value of a component is "about" a given numerical value when the binding activity of the isolated antibody is maintained and detectable after the isolated antibody is placed in the pharmaceutical composition.
[0149] Competitive binding analysis is performed to determine whether IL-23 specific mAbs bind similar or different epitopes and / or compete with each other. Abs are individually coated onto ELISA plates. Competing mAbs are added, followed by biotinylated hrIL-23. For a positive control, the same mAb for coating can be used as a competing mAb ("self-competition"). IL-23 binding is detected using streptavidin. These results indicate whether the mAbs recognize similar or partially overlapping epitopes on IL-23.
[0150] In one embodiment of the pharmaceutical composition, the isolated antibody concentration is about 77 to about 104 mg per mL of pharmaceutical composition. In another embodiment of the pharmaceutical composition, the pH is about 5.5 to about 6.5.
[0151] The stable or preserved formulations can be provided to patients as clear solutions or as dual vials containing a vial of at least one lyophilized anti-IL-23 antibody reconstituted in an aqueous diluent with a second vial containing preservatives or buffers and additives. Either the single solution vial or the dual vial requiring reconstitution can be reused multiple times to satisfy single or multiple patient treatment cycles, thus providing a more convenient treatment regimen than is currently available.
[0152] Other formulations or methods of stabilizing anti-IL-23 antibodies may be other than clear solutions of lyophilized powders containing the antibodies. Non-clear solutions include formulations containing microparticle suspensions, which are compositions containing anti-IL-23 antibodies in structures of various sizes known variously as microspheres, microparticles, nanoparticles, nanospheres, or liposomes. Such relatively homogeneous essentially spherical microparticle formulations containing active agents can be formed by contacting an aqueous phase containing active agents and polymers with a non-aqueous phase, as taught in U.S. Pat. No. 4,589,330, and then evaporating the non-aqueous phase to cause coalescence of particles from the aqueous phase. Porous microparticles can be prepared by using a first phase containing active agents and polymers dispersed in a continuous solvent, and removing the solvent from the suspension by lyophilization or dilution-extraction-precipitation, as taught in U.S. Pat. No. 4,818,542. Preferred polymers for such preparations are gelatin agar, starch, arabinogalactan, albumin, collagen, polyglycolic acid, polylactic acid, glycolide-L(-)lactide, poly(epsilon-caprolactone, poly(epsilon-caprolactone-co-lactic acid), poly(epsilon-caprolactone-co-glycolic acid), poly(β-hydroxybutyric acid), polyethylene oxide, polyethylene, poly(alkyl-2-cyanoacrylate), poly(hydroxyethyl methacrylate), polyamide, poly(amino acids), poly(2-hydroxyethyl DL-aspartamide), poly(ester urea), poly(L-phenylalanine / ethylene glycol), poly( ... The preferred polymers are natural or synthetic copolymers or polymers selected from the group consisting of poly(methyl methacrylate), poly(glycol / 1,6-diisocyanatohexane), and poly(methyl methacrylate). Particularly preferred polymers are polyesters such as polyglycolic acid, polylactic acid, glycolide-L(-)lactide poly(epsilon-caprolactone, poly(epsilon-caprolactone-co-lactic acid), and poly(epsilon-caprolactone-co-glycolic acid). Solvents useful for dissolving the polymer and / or active agent include water, hexafluoroisopropanol, methylene chloride, tetrahydrofuran, hexane, benzene, or hexafluoroacetone sesquihydrate.The process of dispersing the active-containing phase into the second phase can include forcing the first phase through orifices in a nozzle under pressure to affect droplet formation.
[0153] Dry powder formulations may also result from processes other than freeze-drying, such as, for example, spray drying, or solvent extraction by evaporation, or by precipitation of a crystalline composition followed by one or more steps to remove the aqueous or non-aqueous solvent. The preparation of spray-dried antibody formulations is taught in U.S. Pat. No. 6,019,968. Antibody-based dry powder compositions can be produced by spray drying a solution or slurry of antibody and, optionally, excipients in a solvent under conditions to provide a respirable dry powder. Solvents include polar compounds, such as water and ethanol, that are easily dried. Antibody stability can be enhanced by performing the spray-drying procedure in the absence of oxygen, for example under a nitrogen blanket, or by using nitrogen as the drying gas. Another relatively dry formulation is a dispersion of multiple porous microstructures dispersed in a suspension medium that typically includes a hydrofluoroalkane propellant, as taught in WO 9916419. The stabilized dispersion can be administered to the patient's lungs using a metered dose inhaler. Equipment useful in the commercial production of spray dried drugs is manufactured by Buchi Ltd. or Niro Corp.
[0154] Anti-IL-23 antibodies, either in the stable or preserved formulations or in solution described herein, can be administered to a patient in accordance with the present invention via a variety of delivery methods, as are well known in the art, such as SC or IM injection, transdermal, transpulmonary, transmucosal, implants, osmotic pumps, cartridges, micropumps, or other means understood by those of skill in the art.
[0155] Therapeutic Applications The present invention also provides methods for modulating or treating Crohn's disease in a cell, tissue, organ, animal, or patient using at least one IL-23 antibody of the present invention, e.g., by administering or contacting the cell, tissue, organ, animal, or patient with a therapeutically effective amount of an IL-23 specific antibody, as known in the art or described herein.
[0156] Any of the methods of the invention may comprise administering to a cell, tissue, organ, animal or patient in need of such modulation, treatment or therapy an effective amount of a composition or pharmaceutical composition comprising an anti-IL-23 antibody. Such methods may optionally further comprise co-administration or combination therapy for the treatment of such disease or disorder, wherein administering the at least one anti-IL-23 antibody, specified portion or variant thereof, is in combination with at least one TNF antagonist (such as, but not limited to, a chemical or proteinaceous TNF antagonist, a TNF monoclonal or polyclonal antibody or fragment, a soluble TNF receptor (e.g., p55, p70, or p85) or fragment, a fusion polypeptide thereof, or a small molecule TNF antagonist, such as a TNF binding protein. TBP-1 or TBP-II, nerelimonumab, infliximab, etanercept (Enbrel™), adalimumab (Humira™), CDP-571, CDP-870, afelimomab, lenercept, etc.), antirheumatic drugs (e.g., methotrexate, auranofin, aurothioglucose, azathioprine, sodium aurothiomalate, hydroxychloroquine sulfate, leflunomide, sulfasalazine), muscle relaxants, narcotics, non-steroidal anti-inflammatory drugsdrugs, NSAIDs), analgesics, anesthetics, sedatives, local anesthetics, neuromuscular blockers, antibacterials (e.g., aminoglycosides, antifungals, antiparasitics, antivirals, carbapenams, cephalosporins, fluoroquinolones, macrolides, penicillins, sulfonamides, tetracyclines, other antibacterials), psoriasis medications, corticosteroids, anabolic steroids, diabetes medications, minerals, nutritional drugs, thyroid medications, vitamins, calcium-related hormones, antidiarrheals, antitussives, antiemetics, antineoplastics, laxatives, anticoagulants, erythropoietin (e.g., epoetin alfa), filgrastim (e.g., G-CSF, Neupogen), sargramostim (GM-CSF, Leukine), The method further comprises administering, before, simultaneously, and / or after at least one selected from an immunological agent, an immunoglobulin, an immunosuppressant (e.g., basiliximab, cyclosporine, daclizumab), a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, an antimanic, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an epinephrine or an analogue, dornase alfa (Pulmozyme), a cytokine, or a cytokine antagonist. Suitable dosages are well known in the art. See, for example, Wells et al., eds., Pharmacotherapy Handbook, 2 nd Edition, Appleton and Lange, Stamford, CT (2000), PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, CA (2000), Nursing 2001 Handbook of Drugs, 21 stedition, Springhouse Corp., Springhouse, PA, 2001, Health Professional's Drug Guide 2001, ed., Shannon, Wilson, Stang, Prentice-Hall, Inc., Upper Saddle River, NJ, each of which is incorporated herein by reference in its entirety.
[0157] Treatment Typically, the treatment of Crohn's disease is effected by administering an effective amount or dosage of an anti-IL-23 antibody composition, which, on average, ranges from at least about 0.01 to 500 milligrams of anti-IL-23 antibody per kilogram of patient per administration, depending on the specific activity of the active agent contained in the composition, in total, on average, at least about 0.1 to 100 milligrams of antibody per kilogram of patient per administration, preferably at least about 0.1 to 100 milligrams of antibody per kilogram of patient per administration, in single or multiple doses. Alternatively, an effective serum concentration may include a serum concentration of 0.1 to 5000 μg / mL per administration, in single or multiple doses. Suitable dosages are known to medical practitioners and will, of course, depend on the specific disease state, the specific activity of the composition administered, and the specific patient undergoing treatment. In some cases, it may be necessary to provide repeated administrations, i.e., repeated individual administrations of a particular monitored or metered administration, to achieve the desired therapeutic dose, where the individual administrations are repeated until the desired daily dosage or effect is obtained.
[0158] Preferred dosages are optionally 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and / or 100-500 mg / kg / dose, or any range, value, or percentage thereof, or 0.1, 0.5, 0.9, 1.0, 1.1, 1.2, 1.5, 1.9, 2.0, 2.5, 2.9, 3.0, 3.5, 3.9, 4.0, 4.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 8.0, 8.5 ... ,7.9,8.0,8.5,8.9,9.0,9.5,9.9,10,10.5,10.9,11,11.5,11.9,20,12.5,12.9,13.0,13.5,13.9,14.0,14.5,4.9,5.0,5.5.,5.9,6.0,6.5,6.9,7.0 ,7.5,7.9,8.0,8.5,8.9,9.0,9.5,9.9,10,10.5,10.9,11,11.5,11.9,12,12.5,12.9,13.0,13.5,13.9,14,14.5,15,15.5,15.9,16,16.5,16.9,17,1 In some embodiments, the serum concentration may be 7.5, 17.9, 18, 18.5, 18.9, 19, 19.5, 19.9, 20, 20.5, 20.9, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 96, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, and / or 5000 μg / mL serum concentration, or any range, value, or percentage thereof.
[0159] Alternatively, the dose administered may vary depending on known factors such as the pharmacodynamic characteristics of the particular agent and its method and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, type of concurrent treatment, frequency of treatment, and the desired effect. The dose of active ingredient may typically be about 0.1 to 100 milligrams per kilogram of body weight. Typically, 0.1 to 50, preferably 0.1 to 10 milligrams per kilogram per dose, or in sustained release form, is effective to obtain the desired results.
[0160] As non-limiting examples, treatment of humans or animals may be performed using a single dose, intravenous administration, or multiple doses over 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 days. or additionally, on at least one day of eyes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 11 0.1 to 100 mg / kg per day, for example, 0.5, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 1.9, 1.10, 1.20, 1.40, 1.65, 1.80, 1.95, 1.99, 1.99, 1.06, 1.07, 1.08, 1.09, 1.10, 1.11, 1.12, 1.13, 14, 15, 16, 17, 18, 19, or 20 years, or any combination thereof. The antibody may be provided as a single or periodic dose of 0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90, or 100 mg / kg of at least one antibody of the invention.
[0161] Dosage forms (compositions) suitable for internal administration generally contain about 0.001 milligrams to about 500 milligrams of active ingredient per unit or container. In these pharmaceutical compositions, the active ingredient is usually present in an amount of about 0.5 to 99.999% by weight based on the total weight of the composition.
[0162] For parenteral administration, the antibody may be formulated as a solution, suspension, emulsion, particle, powder, or lyophilized powder, provided together with or separately from a pharma- ceutical acceptable parenteral vehicle. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 1-10% human serum albumin. Non-aqueous vehicles such as liposomes and fixed oils can also be used. The vehicle or lyophilized powder may contain additives that maintain isotonicity and chemical stability (e.g., sodium chloride for isotonicity, mannitol, buffers and preservatives for chemical stability). The formulation is sterilized by known or suitable techniques.
[0163] Suitable pharmaceutical carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
[0164] Alternative Administration Many known and developed modes can be used in accordance with the present invention to administer a pharma- ceutical effective amount of an anti-IL-23 antibody. Although pulmonary administration is used in the following description, other modes of administration may be used in accordance with the present invention with suitable results. The IL-23 specific antibodies of the present invention can be delivered in a carrier, as a solution, emulsion, colloid or suspension, or as a dry powder, using any of a variety of devices and methods suitable for administration by inhalation or by other methods described herein or known in the art.
[0165] Parenteral Formulation and Administration Preparations for parenteral administration may contain sterile water or saline, polyalkylene glycols such as polyethylene glycol, vegetable oils, hydrogenated naphthalenes, etc. as common excipients. Aqueous or oily suspensions for injection can be prepared by using appropriate emulsifiers or wetting agents and suspending agents according to known methods. Injections can be non-toxic parenterally administrable diluents such as aqueous solutions, sterile injections, or suspensions in solvents. Usable vehicles or solvents include water, Ringer's solution, isotonic saline, etc., and sterile fixed oils can be used as normal solvents or suspension solvents. For these purposes, any kind of fixed oils and fatty acids, including natural, synthetic, or semi-synthetic fatty oils or fatty acids, natural, synthetic, or semi-synthetic monoglycerides, diglycerides, or triglycerides, can be used. Parenteral administration is known in the art and includes, but is not limited to, conventional injection means, the gas pressurized needleless injection device described in U.S. Pat. No. 5,851,198, and the laser perforator device described in U.S. Pat. No. 5,839,446, which are incorporated herein by reference in their entireties.
[0166] alternative delivery The invention further relates to administration of anti-IL-23 antibodies by parenteral, subcutaneous, intramuscular, intravenous, intra-articular, intrabronchial, intraabdominal, intracapsular, intrachondral, intrasinus, intracavity, intracerebellar, intraventricular, intracolonic, intracervical, intragastric, intrahepatic, intramyocardial, intraosseous, intrapelvic, intrapericardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, intravaginal, rectal, buccal, sublingual, intranasal, or transdermal means. The IL-23 antibody compositions can be formulated for use parenterally (subcutaneously, intramuscularly, or intravenously) or for any other administration, particularly in the form of liquid solutions or suspensions, particularly in semi-solid forms such as, but not limited to, creams and suppositories, for use in vaginal or rectal administration, in forms such as, but not limited to, tablets or capsules, for buccal or sublingual administration, or intranasally, in forms such as, but not limited to, powders, nasal drops or aerosols, or certain agents, or with chemical enhancers such as dimethylsulfoxide to either modify the skin structure or increase the drug concentration in transdermal patches (Junginger, et al. In "Drug Permeation Enhancement;" Hsieh, DS, Eds., pp. 59-90 (Marcel Dekker, Inc. New York, 1999), which are incorporated herein by reference in their entirety). 1994), or application of protein and peptide containing formulations to the skin (WO 98 / 53847), or application of an electric field to create a transient transport pathway, such as electroporation, or to increase the mobility of a charged drug through the skin, such as iontophoresis, or application of ultrasound, such as sonophoresis (U.S. Pat. Nos. 4,309,989 and 4,767,402), for transdermal use, such as, but not limited to, gels, ointments, lotions, suspensions, or patch delivery systems (the above publications and patents are incorporated herein by reference in their entireties).
[0167] Having generally described the present invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to be limiting. Further details of the present invention are illustrated by the following non-limiting examples. The disclosures of all citations herein are expressly incorporated herein by reference.
[0168] Embodiment The present invention provides the following non-limiting embodiments. 1. A method of treating Crohn's disease in a patient, comprising administering to the patient an initial subcutaneous administration of 400 mg of an antibody specific for IL23, a subcutaneous administration of 400 mg about 4 weeks after the initial administration, and a subcutaneous administration of 400 mg about 8 weeks after the initial administration. 2. The method of embodiment 1, further comprising administering 100 mg or 200 mg of the antibody about every 4 weeks or about every 8 weeks after the administration at about 8 weeks. 3. The method of embodiment 2, further comprising administering a dose of 200 mg of the antibody about every 4 weeks after the dose at about 8 weeks. 4. The method of embodiment 2, further comprising administering a dose of 100 mg of the antibody about every 8 weeks after the dose at about 8 weeks. 5. The method of embodiment 1, wherein the patient is identified as a responder to the antibody and meets a clinical endpoint about 12 weeks after the first dose, the clinical endpoint being clinical remission at week 12 defined as a CDAI less than (<) 150 points or endoscopic response as measured by at least a 50% improvement from baseline in Simplified Endoscopic Score for Crohn's Disease (SES-CD). 6. The method of embodiment 1, wherein the patient is identified as meeting a clinical endpoint selected from the group consisting of: (i) clinical remission, defined as a CDAI score of less than (<) 150 points measured about 24 weeks after the first dose; (ii) patient-reported outcome (PRO)-2 remission, defined based on an average daily stool frequency (SF) ≦3 and an average daily abdominal pain (AP) score ≦1, and no worsening of AP or SF from baseline measured about 12 weeks after the first dose; and (iii) clinical response, defined as a reduction from baseline of ≧100 points in CDAI score measured about 12 weeks after the first dose. 7. The antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising: The complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; the CDRL2 amino acid sequence of SEQ ID NO:5, and comprising the CDRL3 amino acid sequence of SEQ ID NO:6, The heavy chain variable region is The complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1; the CDRH2 amino acid sequence of SEQ ID NO:2, and 2. The method of embodiment 1, wherein the antibody comprises a CDRH3 amino acid sequence of SEQ ID NO:3, and the patient is considered a responder to the antibody. 8. The patient is a responder to the antibody and meets the following clinical endpoints: (i) change from baseline in Crohn's Disease Activity Index (CDAI) score; (ii) clinical remission, defined as a CDAI of less than (<) 150 points; (iii) clinical response defined as a reduction from baseline in CDAI score of ≥100 points (≥100) or a CDAI score <150; (iv) Patient-Reported Outcome (PRO)-2 remission, defined based on mean daily stool frequency (SF) and mean daily abdominal pain (AP) scores; (v) clinical biomarker response, defined using clinical response based on CDAI score and reduction from baseline in C-reactive protein (CRP) or fecal calprotectin; (vi) endoscopic response, as measured by the Simplified Endoscopic Score for Crohn's Disease (SES-CD); (vii) endoscopic remission, as measured by the Simplified Endoscopic Score for Crohn's Disease (SES-CD); (viii) sustained clinical remission at week 48, defined as CDAI < 150 for the majority of all visits between weeks 12 and 48; (ix) corticosteroid-free clinical remission at week 48, defined as a CDAI score of <150 at week 48 and no corticosteroids at week 48; (x) fatigue response based on the Patient-Reported Outcomes Measurement Information System (PROMIS); and (xi) Endoscopic response, as measured by the Simplified Endoscopic Score for Crohn's Disease (SES-CD) 8. The method of embodiment 7, wherein the method is identified as satisfying the following: 9. The method of embodiment 8, wherein the clinical endpoint is measured 4, 8, 12, 16, 20, 28, 32, 36, 40, 44, and / or 48 weeks after initial treatment. 10. The method of embodiment 7, wherein the antibody is present in a pharmaceutical composition comprising 7.9% (w / v) sucrose, 4.0 mM histidine, 6.9 mM L-histidine monohydrochloride monohydrate; 0.053% (w / v) polysorbate 80, and the diluent is water at standard conditions. 11. The method of embodiment 1, further comprising administering to the patient one or more additional drugs used to treat Crohn's disease. 12. The method of embodiment 11, wherein the additional medication is selected from the group consisting of immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate (MTX), anti-B cell surface marker antibodies, anti-CD20 antibodies, rituximab, TNF inhibitors, corticosteroids, and costimulatory regulators. 13. The method of embodiment 1, wherein the antibody comprises the light chain variable region amino acid sequence of SEQ ID NO:8 and the heavy chain variable region amino acid sequence of SEQ ID NO:7. 14. The method of embodiment 1, wherein the antibody comprises a light chain amino acid sequence of SEQ ID NO:10 and a heavy chain amino acid sequence of SEQ ID NO:9. 15. The method of embodiment 1, wherein the patient is considered a biologic therapy non-responder or intolerant (Bio-non-responder) for Crohn's disease. 16. The method of embodiment 1, wherein the patient is considered conventional therapy non-responsive or intolerant (Con non-responsive) for Crohn's disease. 17. The method of embodiment 1, wherein said Crohn's disease is moderately to severely active Crohn's disease. 18. The method of embodiment 17, wherein the patient has endoscopic evidence of active Crohn's disease prior to administration of the first dose. 19. The method of embodiment 17, wherein the patient has moderately to severely active Crohn's disease for at least 3 months prior to administration of the first dose. 20. A method of treating moderately to severely active Crohn's disease in a patient, comprising: (i) administering to the patient an initial subcutaneous dose of 400 mg of an antibody specific for IL23, followed by a subcutaneous dose of 400 mg about 4 weeks after the initial dose, and a subcutaneous dose of 400 mg about 8 weeks after the initial dose; and (ii) further administration of a 200 mg dose of the antibody about every 4 weeks after the 8 week dose, or a 100 mg dose of the antibody about every 8 weeks after the 8 week dose, wherein the antibody comprises a light chain variable region amino acid sequence of SEQ ID NO:8 and a heavy chain variable region amino acid sequence of SEQ ID NO:7, and the patient is a responder to the antibody by being identified as meeting a clinical endpoint about 12 weeks after the initial dose, wherein the clinical endpoint is clinical remission at week 12 defined as a CDAI less than (<) 150 points or an endoscopic response as measured by at least a 50% improvement from baseline in the Simplified Crohn's Endoscopy Score (SES-CD). EXAMPLES
[0169] Example 1 Preclinical evidence implicating IL-23 as a target in Crohn's disease Genetic and animal model studies have investigated the contribution of IL-12 and IL-23 in driving the pathophysiology of Crohn's disease. Results indicate that IL-23 plays a major role in inflammatory bowel disease (IBD), and emerging evidence suggests that blocking IL-23 alone may be a more effective strategy than blocking both IL-12 and IL-23.
[0170] Initial observations from genetic and animal model data suggest that Crohn's disease is potentially mediated by IL-12 and / or IL-23, potentially via the Th1 and Th17 pathways that IL-12 and / or IL-23 induce, respectively. However, growing evidence suggests that IL-23 in Crohn's disease plays a major role. Genome-wide association studies have identified polymorphisms in the IL-23R gene that are associated with Crohn's disease. The role of IL-23 in driving intestinal inflammation has been shown in several mouse models. Mice treated with anti-IL-23 antibodies show attenuated inflammation, and mice with genetic deletion of the p19 subunit of IL-23 are protected in several models of intestinal inflammation.
[0171] Clinical experience with IL-12 / 23-targeted therapy (ustekinumab) in Crohn's disease The phase 3 program for ustekinumab in Crohn's disease included two 8-week studies evaluating the efficacy and safety of intravenous (IV) induction of ustekinumab, and one maintenance study evaluating the efficacy and safety of subcutaneous (SC) maintenance of ustekinumab for a total treatment period of 52 weeks. Ustekinumab was evaluated in the full range of biologically eligible patients with Crohn's disease, i.e., patients who were conventional therapy nonresponders and patients who were biologic therapy nonresponders. After a single IV induction dose of ustekinumab 6 mg / kg at week 0, approximately 21% and 40% of BIO nonresponders and CON nonresponders, respectively (versus approximately 7% and 20%, respectively, of placebo-treated participants) achieved clinical remission at week 8 (as assessed by the Crohn's Disease Activity Index [CDAI]). Among participants who responded to ustekinumab IV induction and were re-randomized to receive ustekinumab SC maintenance at 90 mg every 8 weeks (q8w) or 90 mg every 12 weeks (q12w), approximately 53% and 49% of participants, respectively, were in clinical remission at week 52 compared with 36% of participants receiving placebo maintenance.
[0172] Clinical experience with IL-23 targeted therapy in Crohn's disease Clinical trials of IL-12 / 23p40 antagonists (briakinumab and ustekinumab) first established a potential therapeutic role for IL-23 in Crohn's disease. Ustekinumab (STELARA®) was recently approved for the treatment of moderately to severely active Crohn's disease. Although these programs have shown that blockade of both IL-12 and IL-23 is effective in treating Crohn's disease, they have failed to confirm the relative contributions of the two cytokines.
[0173] Recent studies of two anti-IL-23 antagonists, risankizumab (formerly BI-655066) and brazikumab (formerly MEDI2070, AMG 139), have reported phase 2 results demonstrating efficacy of IL-23 blockade in participants with moderately to severely active Crohn's disease, improving clinical signs and symptoms, reducing inflammatory biomarkers, and improving endoscopic findings in participants with primarily biologic refractory Crohn's disease. The magnitude of efficacy observed in each of these studies indicates the potential for improved efficacy compared to ustekinumab (anti-IL-12 / 23), acknowledging the limitations of crossover comparisons and the relatively small size of the IL-23 phase 2 studies.
[0174] Crossover study comparisons of clinical remission rates with IL-23 blockade suggest the possibility of improved efficacy compared to ustekinumab. It is noteworthy that the induction doses used in both studies of risankizumab (200 and 600 mg IV at weeks 0, 4, and 8) and brazikumab (700 mg IV at weeks 0 and 4) were significantly higher than the approved ustekinumab dose (approximately 6 mg / kg IV at week 0). Crossover meta-analysis of compounds suggests that the endpoint of the dose-response curve may be higher, especially with risankizumab.
[0175] Furthermore, phase 2 trials with risankizumab also suggested that maximum response rates may not be reached until after 6 months of treatment.Using a dose of 600 mg IV every 4 weeks (q4w) for up to 6 months, clinical remission rates of approximately 50% were observed in all treated patients, substantially higher than remission rates previously reported with other agents, including ustekinumab, in similar study populations at similar follow-up time points.Of participants who achieved remission at 6 months and continued on risankizumab maintenance treatment (180 mg SC q8w), approximately 70% were in remission at 1 year.
[0176] Currently, the GALAXI clinical program is evaluating intravenous (IV) induction dosing followed by subcutaneous (SC) maintenance dosing of guselkumab in participants with moderately to severely active Crohn's disease who have had an inadequate response or poor tolerance to prior conventional or biologic therapy. There are three separate studies under the GALAXI protocol (Phase 2 study GALAXI 1 and Phase 3 studies GALAXI 2 and GALAXI 3). Results from the GALAXI 1 study show that guselkumab IV induction demonstrated greater improvements compared to placebo across key clinical efficacy and endoscopic outcome measures at week 12.
[0177] Comprehensive Rationale for Guselkumab in Crohn's Disease In summary, genetic and preclinical evidence together suggest a major role for selectively targeting IL-23 in modulating the underlying pathophysiology of IBD. Available clinical experience with two IL-23 antagonists and established evidence from an approved IL-12 / 23 antagonist (ustekinumab) demonstrate proof of mechanism and proof of concept, respectively, for targeting IL-23 in the treatment of Crohn's disease. Together, the available evidence provides support for the trial of guselkumab in the treatment of Crohn's disease.
[0178] In the current study, the sponsor's interest is to evaluate SC administration of guselkumab for the induction phase of Crohn's disease treatment. Subcutaneous delivery of biologics has become a valuable alternative to IV administration across many disease areas. Although the pharmacokinetic (PK) profiles of the SC and IV administration routes are different, SC administration has been proven to be effective, safe, well tolerated, and is generally preferred by patients and healthcare providers due to greater dosing flexibility and easier administration for the patient or their caregiver in their preferred setting. In addition, SC administration has resulted in reduced healthcare costs and resource utilization associated with drug delivery. In short, SC administration has become an attractive alternative to more invasive and time-consuming IV infusions.
[0179] Given the results of GALAXI 1 and the potential benefits of SC induction for patients and healthcare systems, the objective of this study was to evaluate the efficacy, safety, and PK / pharmacodynamics (PD) profile of guselkumab SC induction compared with placebo in participants with moderately to severely active Crohn's disease.
[0180] Clinical Protocol Protocol Title-GRAVII A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
[0181] Synopsis Short title: A phase 3 study to evaluate the efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active Crohn's disease
[0182] Throughout the protocol, the term "study intervention" refers to the study medication.
[0183] Objectives and Endpoints The objective of this study is to evaluate the effect of guselkumab SC in moderately to severely active Crohn's disease. The week 12 endpoint is based on a comparison of the combined guselkumab induction arm (guselkumab 400 mg SC at weeks 0, 4, and 8) to the placebo arm. The week 24 endpoint is based on a comparison of each guselkumab arm (guselkumab 400 mg SC at weeks 0, 4, and 8, followed by guselkumab 200 mg SC every 4 weeks [q4w] in one arm and 100 mg SC every 8 weeks [q8w] in the other arm) to the placebo arm. Tertiary endpoints include, but are not limited to, those specified below. Analyses will be performed at applicable time points through week 24.
[0184] [Table 2]
[0185] hypothesis The co-primary hypotheses of the study are that among participants with moderately to severely active Crohn's disease, guselkumab is superior to placebo in inducing clinical remission at week 12 and that guselkumab is superior to placebo in inducing endoscopic response at week 12.
[0186] Overall Plan This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab subcutaneous (SC) induction dosing. The target population is adult participants with moderate to severe active Crohn's disease (lasting at least 3 months) with colitis, ileitis, or ileocolitis, previously confirmed by radiography, histology, and / or endoscopy. To be eligible for the study, participants must also have endoscopic evidence of active Crohn's disease and have documented inadequate response or intolerance to prior conventional therapy (oral corticosteroids or the immunomodulators azathioprine [AZA], 6-mercaptopurine [6-MP], or methotrexate [MTX]; CON non-response) or biologic therapy (infliximab, adalimumab, certolizumab pegol, vedolizumab, or approved biosimilars for these agents; BIO non-response).
[0187] The two groups, based on prior treatment involving the target population, are briefly described below.
[0188] Non-response or intolerance to conventional therapy (CON non-response) Participants must have had an inadequate response to or been poorly tolerated with at least one of the following conventional Crohn's disease therapies: oral corticosteroids (including prednisone, budesonide, and beclomethasone dipropionate) or the immunomodulatory agents azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX).
[0189] Participants who demonstrated corticosteroid dependence (i.e., the inability to successfully taper corticosteroids without recurrence of Crohn's disease symptoms) were also eligible.
[0190] Participants may be naïve to biologic therapy (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, or approved biosimilars for these agents) or may have been exposed to biologic therapy and not had an inadequate response or intolerance.
[0191] Nonresponse or intolerance to biological therapy (BIO nonresponse) Participants must have had an inadequate response or been poorly tolerated to at least one or more biologic therapies (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, or approved biosimilars for these agents) at least in doses approved locally for the treatment of Crohn's disease. Inadequate response is defined as primary nonresponse (i.e., no initial response) or secondary nonresponse (i.e., initial response followed by loss of response).
[0192] Participants with previous exposure to IL-12 / 23 or IL-23 agents were ineligible for this study.
[0193] Overall, the study will evaluate guselkumab SC treatment through 12 weeks of induction and at least 12 weeks of maintenance. At week 24, all participants will enter the extension phase and receive the same treatment regimen they were receiving at week 24. The study will be unblinded after the last participant completes the week 48 assessment and the week 48 database lock (DBL) is completed. At the time the study is unblinded, placebo participants who have not been rescued with guselkumab will discontinue study intervention and attend a final efficacy and safety (FES) follow-up visit. All other participants will continue guselkumab treatment through week 96.
[0194] The total study duration will be up to 109 weeks. The study will include the following phases: 1. Screening phase: up to 5 weeks 2. Main treatment phase: 24 weeks 3. Extension phase: 72 weeks 4. Post-treatment Phase (FES Follow-up Visit): Up to approximately 12 weeks after the last administration of study intervention
[0195] In general, participants receiving oral 5-aminosalicylates, oral corticosteroids, conventional immunomodulators (AZA, 6-MP, or MTX), antibiotics, and / or enteral nutrition for the treatment of Crohn's disease at baseline should maintain stable dosing over the specified period prior to baseline and through week 48, with the exception of oral corticosteroids. All participants taking corticosteroids at week 0 should begin tapering their corticosteroid dosing, beginning at week 12. This tapering is mandatory unless medically not feasible. Participants who discontinue the study intervention early should return for a study intervention discontinuation (SID) visit. All randomized participants should complete an FES follow-up visit approximately 12 weeks after the last dose of study intervention.
[0196] Efficacy, safety, pharmacokinetics (PK), immunogenicity, and biomarkers will be assessed according to the Schedule of Activities (SoA). Blood samples for pharmacogenomic studies will be collected only from participants who consent to this component of the protocol (if permitted by local regulations).
[0197] Database locks are planned for weeks 24, 48, and when the last participant completes their last scheduled assessment as indicated in the SoA. Additional DBLs may be added if necessary.
[0198] Number of participants The target sample size is 318 participants. Participants who had an inadequate response or poor tolerance to biologic therapy comprise approximately 35% to 65% of the population.
[0199] Intervention group and duration The total study duration will be up to 109 weeks. The study will include the following phases: 1. Screening phase: up to 5 weeks 2. Main treatment phase: 24 weeks 3. Extension phase: 72 weeks 4. Post-treatment Phase (FES Follow-up Visit): Up to approximately 12 weeks after the last administration of study intervention
[0200] At week 0, eligible participants will be randomized in a 1:1:1 ratio to one of the following SC treatments: 106 participants received guselkumab 400 mg SC at weeks 0, 4, and 8, followed by guselkumab 200 mg SC every 4 weeks (q4w) through week 24. 106 participants received guselkumab 400 mg SC at weeks 0, 4, and 8, followed by guselkumab 100 mg SC every 8 weeks (q8w) through week 24 106 participants were randomly assigned to placebo SC q4w from week 0 to week 24.
[0201] Table 2 describes the study interventions.
[0202] [Table 3]
[0203] Randomization will be stratified by baseline Crohn's Disease Activity Index (CDAI) score (≦300 or >300), baseline Simplified Crohn's Disease Endoscopy Score (SES-CD) score (≦12 or >12), and BIO non-response status (yes or no) at baseline (week 0).
[0204] During the extension phase, all participants continue to receive the same treatment regimen they were receiving at week 24.
[0205] At the study open-label time after DBL at week 48, placebo participants who have not been rescued with guselkumab will discontinue study intervention and attend a FES follow-up visit. All other participants will continue guselkumab treatment through week 96.
[0206] All participants in the placebo group who meet at least one of the rescue criteria at weeks 12 and 16 will receive rescue treatment, i.e., guselkumab 400 mg SC at weeks 16, 20, and 24, followed by guselkumab 100 mg SC every 8 weeks (q8w). To maintain blinding, participants randomized to guselkumab who meet at least one of the rescue criteria will continue their assigned treatment regimen and receive a blinded sham rescue matching placebo SC injection.
[0207] In the ustekinumab Phase 3 Crohn's Disease Program (IM-UNITI) maintenance study, the sponsor evaluated the effect of a single dose adjustment of ustekinumab (an IL-12 / 23 antagonist) in participants with Crohn's disease. Participants were randomized to receive placebo, ustekinumab 90 mg q12w, or ustekinumab 90 mg q8w (approved dose). In the ustekinumab 90 mg q8w group, 28 participants met prespecified loss of response criteria and underwent a sham dose adjustment. After 16 weeks, 32.1% were in clinical remission and 46.4% had a clinical response after 16 weeks. These results indicate that some participants with inadequate / lost clinical response may benefit from continuing the same dosing regimen over time. Therefore, the guselkumab arm in this study will not undergo a dose adjustment but will undergo a blinded sham rescue.
[0208] Based on data from a Phase 2 dose-ranging study of guselkumab IV in Crohn's disease (GALAXI 1), a single SC induction guselkumab dosing regimen (400 mg SC at weeks 0, 4, and 8) was selected for this study. Week 12 analysis of GALAXI 1 demonstrated similar efficacy with guselkumab induction doses of 1200 mg, 600 mg, and 200 mg administered IV at weeks 0, 4, and 8, respectively. There was no clear dose / exposure response within the range of guselkumab IV induction doses tested. As a result, the 200 mg IV induction dosing regimen was selected for confirmatory evaluation in the Phase 3 guselkumab studies (GALAXI 2 and 3).
[0209] With an estimated bioavailability of guselkumab SC (TREMFYA® SmPC 2021; TREMFYA® USPI 2020) of approximately 50%, guselkumab administered at 400 mg SC is expected to provide comparable total guselkumab exposure (AUC) to the 200 mg IV administration. Population PK modeling and simulations demonstrate that although peak concentrations were higher than the 200 mg IV induction dosing regimen, trough concentrations following the 400 mg SC induction dosing regimen were non-inferior when compared to the IV induction dosing regimen. Experience from biologics approved for both IV and SC administration demonstrates that achieving similar total exposure (mean steady-state serum test intervention concentration [Cavg,ss]) with non-inferior trough concentrations provides comparable efficacy for both routes of administration. In addition, serum peak concentrations during the induction phase may not be the primary driver of efficacy of biologics in IBD. With this in mind, a single guselkumab induction dose regimen of 400 mg SC at weeks 0, 4, and 8 will be evaluated in participants with moderately to severely active Crohn's disease.
[0210] Two guselkumab maintenance dosing regimens (200 mg SC q4w and 100 mg SC q8w) will be evaluated in this study. These are the same doses being evaluated in the ongoing Phase 3 GALAXI study. The selection of the same maintenance dosing regimens allows for a crossover study comparison of SC induction followed by SC maintenance regimen (this study) versus IV induction followed by SC maintenance regimen (GALAXI study). Overall, the two guselkumab maintenance dosing regimens (i.e., 200 mg SC q4w and 100 mg SC q8w) provide an approximately four-fold dose range of exposure, which supports dose / exposure response evaluation of maintenance therapy in the treatment of Crohn's disease.
[0211] Randomization is used to minimize bias in the allocation of participants to each intervention group, increase the likelihood that known and unknown participant attributes (e.g., demographic and baseline characteristics) will be equally balanced between intervention groups, and increase the validity of statistical comparisons between intervention groups. In addition, to minimize imbalance between intervention groups, randomization is stratified by factors that affect prognosis or treatment response (i.e., stratified by baseline CDAI score, SES-CD score, and BIO non-response status).
[0212] Screening of eligible participants will be conducted within 5 weeks prior to administration of the study intervention. The inclusion and exclusion criteria for enrolling participants in this study are described below.
[0213] Inclusion criteria Each potential participant must meet all of the following criteria to be enrolled in the study: 1. Males or females (according to reproductive organs and functions assigned by chromosome pairs) aged 18 years or older (or the legal age of consent in the jurisdiction in which the study is being conducted). 2. Have Crohn's disease or fistulizing Crohn's disease of at least 3 months duration (defined as a minimum of 12 weeks) with colitis, ileitis, or ileocolitis confirmed by radiography, histology, and / or endoscopy at any time in the past. 3. Have clinically active Crohn's disease defined as a baseline CDAI score ≥ 220 and ≤ 450: a. The average number of daily stools is ≥ 4, based on the CDAI component unweighted by the number of liquid or very loose stools or b. Average daily AP score ≥ 2 based on unweighted CDAI components of AP 4. Have endoscopic evidence of active ileocolonic Crohn's disease as assessed by institutional endoscopy readings at screening endoscopy defined as a Screening SES-CD score ≥ 6 (or ≥ 4 for participants with isolated ileal disease) based on the presence of ulceration in at least one of the five ileocolonic segments, resulting in the following designated ulceration component scores: a. Minimum score of 1 for the component "Ulcer size" and b. Minimum score of 1 for the "ulcerated surface" component 5. Participants who had extensive colitis for 8 years or more or disease limited to parts of the colon for 10 years or more Have you had a complete colonoscopy to evaluate for the presence of dysplasia within 1 year prior to the first dose of study intervention? or b. Must undergo a complete colonoscopy with surveillance biopsies for dysplasia as a baseline endoscopy during the screening period. Results from these surveillance biopsies must be negative for dysplasia (low grade, high grade, or "indeterminate dysplasia in reactive atypia") prior to the first dose of study intervention.
[0214] Concomitant or previous medications administered 6. Previous or current medications for Crohn's disease must include at least one of the following: Current treatment with oral corticosteroids (including budesonide and beclomethasone dipropionate) and / or immunomodulators (AZA, 6-MP, MTX) or b. History of failure or poor tolerance to at least one of the following therapies: oral corticosteroids (including budesonide and beclomethasone dipropionate) or immunomodulatory agents (AZA, 6-MP, MTX) or c. History of corticosteroid dependence (i.e., inability to successfully taper corticosteroids without recurrence of Crohn's disease symptoms) or d. Have previously demonstrated lack of initial response (i.e., primary non-responders), responded initially but lost response with continued therapy (i.e., secondary non-responders), or been intolerant to one or more biologic agents (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, or approved biosimilars for these agents) administered at least once locally for the treatment of Crohn's disease Note: Participants meeting criteria 6a-c may have been naïve to or previously exposed to biologic therapy (i.e., infliximab, adalimumab, certolizumab pegol, vedolizumab, or approved biosimilars for these agents) and had not demonstrated an inadequate response or intolerance. 7. Comply with all of the following requirements for concomitant medications to treat Crohn's disease. The following medications are permitted provided that dosing meeting the requirements listed below is stable or has been discontinued prior to baseline within the time frames specified below: a. Stable dosing of an oral 5-ASA compound for at least 2 weeks; or if recently discontinued, must have been stopped for at least 2 weeks. b. Oral corticosteroids at a prednisone equivalent dose of 40 mg / day or less, or budesonide 9 mg / day, or beclomethasone dipropionate 5 mg / day, and stable treatment for at least 2 weeks; or if recently discontinued, must have been discontinued for at least 2 weeks. c. At least 12 weeks of conventional immunomodulatory agents (i.e., AZA, 6-MP, or MTX) and at least 4 weeks of stable dosing; or, if recently discontinued, must have been off for at least 4 weeks. d. If antibiotics are being taken as first-line treatment for Crohn's disease, treatment must be stable for at least 3 weeks; or, if recently discontinued, must have been stopped for at least 3 weeks. e. If taking enteral nutrition as primary treatment for Crohn's disease, it must have been taken for at least 2 weeks; OR, if recently discontinued, it must have been stopped for at least 2 weeks.
[0215] Laboratory Test Screening 8. Have laboratory screening test results within the following parameter ranges, with one retest of laboratory values permitted during the approximately 5-week screening period if one or more of the laboratory parameters are out of range: Hemoglobin ≥ 8.0 g / dL b. White blood cells (WBC) ≧3.0×103 / μL c. Neutrophils ≧1.5×103 / μL d. Platelets ≧100×103 / μL e. Serum creatinine ≦ 1.5 mg / dL f. Alanine transaminase (ALT) (or aspartate transaminase (AST)) ≦2 × upper limit of normal (ULN) g. Total bilirubin (TBili) ≤ 1.5 x ULN (Isolated total bilirubin > 1.5 x ULN is acceptable in participants with known Gilbert syndrome. Gilbert syndrome is suggested by direct bilirubin < 30%).
[0216] tuberculosis A potential participant is considered eligible if the participant meets all of the following TB screening criteria: Note: Interferon-gamma release assay (IGRA) tests include either QuantiFERON-TB® or T-SPOT®.TB. a. Have no history of active TB or exhibit signs or symptoms suggestive of active TB upon medical history and / or physical examination at screening. b. No history of latent TB prior to screening. Exceptions are made for participants with a history of latent TB who meet one of the following criteria: 1. Are you currently receiving treatment for latent TB? or 2. Initiate treatment for latent TB prior to first dose of study intervention NOTE: For participants with a history of treated latent TB, appropriate documentation of treatment must occur prior to the first dose of study intervention. It is the investigator's responsibility to verify the adequacy of prior TB treatment and provide appropriate documentation. IGRA testing is not required at screening for participants with a history of treated latent TB or currently being treated for latent TB. c. Have not had recent close contact with anyone with active TB. If contact has occurred, such participants will be referred to a physician with expertise in TB to determine whether treatment is warranted. This assessment must be appropriately documented, and if treatment is recommended, participants must receive appropriate treatment prior to the first dose of study intervention. d. Have a negative IGRA test result within 2 months prior to the first dose of the study intervention, or 1. Have a history of adequately treated latent TB as described above. 2. Have a newly identified positive IGRA test result that has eliminated active TB and appropriate treatment for latent TB has been initiated prior to the first dose of study intervention. 3.Has a false positive IGRA test as determined by: ◆ Initial IGRA tests suspected to be false positive should be repeated. If the repeat test is not positive, the participant should be referred to a physician with TB expertise to determine whether the initial test can be considered a false positive. This evaluation should be appropriately documented before the first administration of the study intervention. However, if the repeat test is positive, it will be considered a true positive and the participant will be eligible only if active TB has been eliminated and appropriate treatment for latent TB has been initiated as described above. Note: Indeterminate / borderline results should be addressed. e. Chest x-ray (both postero-anterior and lateral views, or per local / national regulations, if applicable) or chest computed tomography (CT) within 3 months prior to the first dose of study intervention showing no abnormalities suggestive of active or inactive TB.
[0217] contraception 9. Female fertility requires a negative serum pregnancy test result at screening. 10. Prior to randomization, women must: A. Inability to give birth or b. Have childbearing capacity, and If heterosexually active, implement a highly effective method of contraception (with a failure rate of <1% per year when used consistently and correctly) and agree to maintain a highly effective method while receiving study intervention and until 12 weeks after the last dose (end of relevant systemic exposure). Note: The method selected must meet local / regional regulations / guidelines for highly effective contraception. NOTE: If a participant's fertility changes after the start of the study (e.g., a premenarchal woman reaches menarche) or pregnancy risk changes (e.g., a non-sexually active woman becomes sexually active), women will need to start using a highly effective method of contraception. 11. Women must agree not to donate eggs (egg cells, oocytes) for assisted reproductive purposes during the study and for 12 weeks after the last dose of the study intervention. 12. During the study and for at least 12 weeks after the last dose of study intervention, male participants will: a. Persons who are sexually active with females of childbearing potential must agree to use a barrier method of contraception (i.e., condoms with spermicide foam / gel / film / cream / suppository or female condoms with spermicide foam / gel / film / cream / suppository / occlusive cap [septum or cervical / vault cap]). b. Anyone who is sexually active with a pregnant woman should use a condom. 13. They must agree not to donate sperm for reproductive purposes. Each participant must sign an informed consent form (ICF), indicating that he or she understands the purpose of the study and the procedures involved, and is willing to take part in the study. Note: In regions where the legal age of consent is greater than 18 years, informed consent must be obtained and signed by both the participant and their legally acceptable representative. 14. If an individual consents to providing a voluntary DNA sample for research, they will be required to sign a separate ICF (if local regulations permit). Refusal to consent to a voluntary DNA research sample will not exclude a participant from participation in the study. Note: In regions where the legal age of consent is greater than 18 years, informed consent must be obtained and signed by both the participant and their legally acceptable representative. 15. Willing and able to comply with all assigned requirements, including but not limited to completing evaluations, adhering to visit schedules, and adhering to lifestyle restrictions.
[0218] Exclusion criteria Potential participants who meet any of the following criteria will be excluded from participating in the study. 1. The presence of complications of Crohn's disease, such as symptomatic strictures or stenosis, short bowel syndrome, or any other manifestation that may be predicted to require surgery, may preclude the use of the CDAI to assess response to therapy, potentially confounding the ability to assess the effect of treatment with guselkumab. 2. Current or suspected abscess. Recent skin and anal abscesses will not be excluded if they have been drained and adequately treated at least 3 weeks prior to baseline, or for intra-abdominal abscesses, 8 weeks prior to baseline, unless a need for further surgery is anticipated. Participants with active fistulas may be included if no need for surgery is anticipated and if there are no currently identified abscesses. 3. Has undergone bowel resection of any kind within 24 weeks prior to first dose of study intervention, or any other intraperitoneal or other major surgery within 12 weeks. 4. You have a draining (i.e., functioning) stoma or ostomy. 5. Presence of adenomatous colonic polyps at screening endoscopy if not removed prior to study entry, or history of adenomatous colonic polyps that were not removed. 6. Have a positive stool culture or other test for an enteric pathogen containing Clostridioides difficile (formerly Clostridium dificile) toxin within 4 months prior to the first dose of study intervention, unless repeat tests are negative and there is no evidence of ongoing infection with that pathogen. NOTE: Treatment and repeat testing may occur during the current screening period.
[0219] Concomitant or previous medications administered 7. If you have taken any of the following prescription drugs or therapies within the specified period: a. Received IV corticosteroids within 3 weeks of baseline b. Received cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of baseline c. Received 6-thioguanine within 4 weeks of baseline d. Biological agents: 1. Received anti-TNFα therapy (e.g., infliximab, etanercept, certolizumab pegol, adalimumab, golimumab) within 8 weeks of baseline 2.Received vedolizumab within 12 weeks from baseline 3.Received other immunomodulatory biologics, including approved and investigational biologics, within 12 weeks or 5 half-lives of baseline, whichever is longer. e. Received any investigational intervention within 4 weeks of baseline or within 5 half-lives of baseline, whichever is longer. f. Received non-autologous stem cell therapy (e.g., Prochymal), natalizumab, efalizumab, or biologic agents that deplete B or T cells (e.g., rituximab, alemtuzumab, or visilizumab) within 12 months of baseline. g. Crohn's disease was treated with apheresis (eg, Adacolumn apheresis) or total parenteral nutrition within 3 weeks of baseline. 8. Previously received biologic agents targeting IL-12 / 23 or IL-23, including but not limited to ustekinumab, briakinumab, brazikumab, guselkumab, mirikizumab, and risankizumab.
[0220] Infection or predisposition to infection: 9. History of latent or acute granulomatous infection prior to screening. This includes histoplasmosis or coccidioidomycosis. Participants with radiographic evidence of possible previous histoplasmosis or coccidioidomycosis will be excluded. 10. Has a history of or ongoing chronic or recurrent infections, including but not limited to respiratory tract infections, bronchiectasis, recurrent renal / urinary tract infections (e.g., pyelonephritis, cystitis), or open, draining, or infected skin wounds, or ulcers. 11. A chest x-ray must be obtained within 12 weeks prior to the first dose of study intervention. Results showing abnormalities suggestive of malignancy, previously unrecognized pulmonary pathology, and undiagnosed pulmonary pathology including, but not limited to, active or latent infection from TB, histoplasmosis, or coccidioidomycosis will be excluded. A chest CT scan obtained off-protocol in lieu of a chest x-ray is also acceptable. See Inclusion Criterion 9 for information regarding eligibility of history of latent TB. 12. History of positive human immunodeficiency virus (HIV) antibodies or positive HIV test at screening. 13. Be seropositive for antibodies to hepatitis C virus (HCV) unless one of the following conditions is met: a. Have a history of successful treatment, defined as being negative for HCV RNA at least 12 weeks after completing antiviral treatment, and have a negative HCV RNA test result at screening; or b. Being seropositive while having a negative HCV RNA test result at least 12 weeks prior to screening and having a negative HCV RNA test result at the time of screening. 14. Have a positive test result for hepatitis B virus (HBV) infection (Appendix 4 [Section 10.4]). Note: Participants who are ineligible for this study due to HIV, HCV, or HBV test results are encouraged to consult with a physician with expertise in the treatment of these infections. 15. Receipt of Bacille Calmette-Guerin (BCG) vaccination within 12 months, or any other live bacterial or live viral vaccination within 4 weeks prior to screening, or scheduled to receive such a vaccine during the study. 16.Current or past nontuberculous mycobacterial infection or clinically significant opportunistic infection (e.g., cytomegalovirus colitis, pneumocystiosis, invasive aspergillosis). 17. Have ever had a clinically significant infection (i.e., hepatitis, sepsis, pneumonia, or pyelonephritis), been hospitalized for an infection, or been treated with parenteral antibiotics for an infection within 8 weeks prior to the first dose of study intervention. Treated and resolved infections that are not deemed clinically significant at the investigator's discretion do not need to be excluded (i.e., acute upper respiratory tract infection, uncomplicated urinary tract infection). 18. Currently has signs or symptoms of clinically significant infection. Ongoing infections that are not deemed clinically significant at the investigator's discretion do not need to be excluded (i.e., acute upper respiratory tract infection, uncomplicated urinary tract infection). 19.Has evidence of herpes zoster infection within 8 weeks prior to the first dose of study intervention. 20. During the 6 weeks prior to baseline, had either (a) confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) infection (positive test), or (b) suspected SARS-CoV-2 infection (clinical features without documented laboratory results), or (c) close contact with a person with known or suspected SARS-CoV-2 infection. Exception: May be included if they have a documented negative result from a validated SARS-CoV-2 test. Obtained at least 2 weeks after conditions (a), (b), or (c) above (timed from resolution of significant clinical features, if present, e.g., fever, cough, dyspnea) and b. None of the above conditions (a), (b), or (c) are present during the period between the negative test result and the baseline examination visit. Note about COVID-19 related exclusions: The field of COVID-19 related testing (for the presence of and immunity to the SARS-CoV-2 virus) is rapidly evolving. Additional testing, if deemed necessary by the Investigator, may be performed as part of screening and / or during the study, in accordance with current regulations / guidance / standard of care from authorities. Note: For those who may be at higher risk for severe COVID-19 illness, follow guidance from local health authorities when weighing the potential benefits and risks of enrolling in a study and during study participation.
[0221] Malignancy or high probability of malignancy: 21.Currently have a malignancy or have a history of malignancy within 5 years prior to screening (excluding non-melanoma skin cancer that has been adequately treated and has no evidence of recurrence for at least 3 months [defined as a minimum of 12 weeks] prior to the first dose of study intervention, or cervical intraepithelial neoplasia that has been treated and has no evidence of recurrence for at least 3 months prior to the first dose of study intervention). 22. Known history of lymphoproliferative disorders including lymphoma, history of monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive of a possible lymphoproliferative disorder such as lymphadenopathy or splenomegaly.
[0222] Coexisting medical conditions or past medical history 23. Have a history of severe, progressive, or uncontrolled renal, genitourinary, hematological, endocrine, cardiac, vascular, pulmonary, rheumatic, neurological, psychiatric, or metabolic disorder, or signs and symptoms thereof. 24.Has had a transplanted organ (except for a corneal transplant performed >12 weeks prior to screening). 25. Poorly tolerates venipuncture or lacks adequate venous access for the collection of blood samples required during the study period. 26. History of drug or alcohol abuse according to the criteria of the Diagnostic and Statistical Manual of Disorders (5th ed.) within 1 year prior to screening. 27. Have unstable suicidal ideation or behavior in the past 6 months, which may be defined as Columbia-Suicide Severity Rating Scale (C-SSRS) scores at screening for suicidal ideation with intent to carry out (ideation level 4), suicidal ideation with a specific plan and intent (ideation level 5), or suicidal behavior (actual suicide attempt, aborted suicide attempt, failed suicide attempt, or preparatory behavior to carry out a suicide attempt) and are deemed to be at risk by the investigator based on assessment by a mental health professional. In addition, participants with C-SSRS scores for wishing for death ("ideation level 1"), nonspecific active suicidal thoughts ("ideation level 2"), active suicidal ideation by any means without intent to carry out (without a plan) ("ideation level 3"), or non-suicidal self-harm behaviors determined by the investigator to be at risk may not be randomized. 28. Known allergy, hypersensitivity, or intolerance to guselkumab or its excipients. 29.Women who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 12 weeks after the last dose of study intervention. 30.Men who plan to father a child while enrolled in this study or within 12 weeks after the last dose of study intervention.
[0223] General 31.Currently participating in or intending to participate in any other study using an investigational product or procedure during the conduct of this study. 32.Has any condition where, in the opinion of the investigator, participation would not be in the participant's best interest (e.g., would compromise their health) or which may prevent, limit, or confound the evaluations specified in the protocol. 33. An employee of the investigator or trial site who is directly involved in the proposed study or other studies at the direction of the investigator or trial site, as well as a family member of that employee or principal investigator.
[0224] A 24-week study period is considered sufficient to evaluate the efficacy and safety of SC induction followed by SC maintenance of guselkumab in Crohn's disease. The guselkumab dosing regimen after week 8 in this study is identical to that in the ongoing guselkumab Phase 3 Crohn's disease studies (GALAXI 2 and 3). After week 24, there are no expected differences in guselkumab concentrations and exposure between the 400 mg SC induction (main study) and 200 mg IV induction (GALAXI) dosing regimens. As a result, this study will be a 24-week study with a 72-week extension. The extension will provide approximately 2 years of access to treatment for participants deemed by the investigator to be benefiting from the study intervention. The follow-up phase (approximately 12 weeks after the last dose of study intervention) is designed to collect samples to measure PK and antibodies to guselkumab, in addition to assessing final efficacy and safety data.
[0225] Biomarkers and DNA collection Biomarker samples (where permitted by local regulations) will be collected to assess the cellular and molecular mechanism of action of guselkumab, or to help explain inter-individual variability in clinical outcomes, or to help identify population subgroups with different responses to the intervention. Serum biomarkers will be collected from whole blood of all participants to assess PD markers associated with the IL-23 pathway and response to guselkumab. Whole blood samples will be collected from all participants to assess the effect of the study intervention on ribonucleic acid (RNA) expression profiles. Ileal colon biopsies will also be obtained from all participants to assess cellular and molecular changes in intestinal mucosal tissue. The goal of biomarker analysis is to further define the mechanism of action of selective blockade of IL-23 by guselkumab in Crohn's disease and to help evaluate the intervention-clinical response relationship.
[0226] An optional pharmacogenomics substudy is planned. It is recognized that genetic variation may be an important contributor to interindividual differences in intervention distribution and response, and may also serve as a marker for disease susceptibility and prognosis. The goal of the pharmacogenomics component is to collect DNA to enable identification of genetic factors that may affect the PK, PD, efficacy, safety, or tolerability of guselkumab, and to identify genetic factors associated with Crohn's disease or response to guselkumab treatment. The focus of this analysis is the evaluation of genetic single nucleotide polymorphisms associated with Crohn's disease and response to treatment with guselkumab.
[0227] Biomarkers and DNA samples can be used to help address new problems and enable the development of safer, more effective and ultimately personalized therapies.
[0228] Patient-reported outcomes of health-related quality of life Patient-reported outcome measures (i.e., IBDQ, PROMIS-29) will be used to assess the benefit of guselkumab treatment on disease-specific and global health-related quality of life (HRQOL). Patient-reported outcome measures are only collected in countries where translations of the measures are available.
[0229] Tapering oral corticosteroids Participants on corticosteroids will undergo mandatory tapering starting from week 12 onwards according to a pre-specified recommended tapering schedule, given that obtaining corticosteroid-free clinical remission is an important goal of therapy.
[0230] Description of the intervention Guselkumab is provided in two dosage strengths: guselkumab 200 mg / 2 mL in a single-dose prefilled syringe with a YpsoMate autoinjector (PFS-Y) and 100 mg / 1 mL in a single-dose prefilled syringe with an UltraSafe Plus™ Passive Needle Guard (PFS-U). Matching placebo is provided as a single-dose 2 mL in PFS-Y and as a single-dose 1 mL in PFS-U.
[0231] Efficacy evaluation Efficacy assessment includes the following: ·CDAI PRO-2 (unweighted CDAI component of total liquid or very loose stool count and abdominal pain [AP] score) Endoscopic evaluation of the intestinal mucosa based on the presence or absence of mucosal ulcers and SES-CD Histological evaluation Inflammatory pharmacodynamic (PD) markers, including C-reactive protein (CRP) and fecal calprotectin; Fistula assessment PRO measures to assess health-related quality of life outcomes, including the Inflammatory Bowel Disease Questionnaire (IBDQ) and Patient-Reported Outcomes Measurement Information System (PROMIS)-29; Patient-reported symptom scales including the Bristol Stool Formation Scale (BSFS) and AP-Numeric Rating Scale (NRS)
[0232] Pharmacokinetic evaluation Serum samples will be analyzed to determine guselkumab concentrations using a specific and sensitive immunoassay method that has been validated by or under the supervision of the sponsor.
[0233] Pharmacogenomic (DNA) evaluation Pharmacogenomic blood samples will be collected, where appropriate (if permitted by local regulations), only from participants who consent separately to this component of the study to enable pharmacogenomic studies. Participation in the pharmacogenomic study is voluntary. Deoxyribonucleic acid (DNA) samples will be analyzed for the identification of genetic factors that may be associated with clinical response.
[0234] Pharmacodynamic and biomarker evaluation Inflammatory PD markers (CRP and fecal calprotectin) will be assessed using blood and fecal samples. Biomarker evaluation will be performed to examine biological response to treatment and to identify biomarkers associated with guselkumab treatment and / or Crohn's disease. Evaluation will include evaluation of relevant biomarkers in serum, whole blood, and ileal colon biopsy samples, where permitted by local regulations.
[0235] Immunogenicity assessment Serum samples will be screened for antibodies that bind guselkumab and titers of confirmed positive samples will be reported. Other analyses may be performed to verify the stability of antibodies to guselkumab and / or to further characterize the immunogenicity of guselkumab.
[0236] Safety assessment Safety assessments will include adverse events (AEs), clinical laboratory tests, vital signs and physical examination, screening electrocardiogram, suicidality assessment, concomitant medication review, injection site reactions, monitoring for hypersensitivity reactions, tuberculosis assessment, and other infection assessments.
[0237] statistical methods Sample size determination Sample size was determined by the power to detect significant differences in clinical remission at week 12 and endoscopic response at week 12 (co-primary endpoints) between the combined guselkumab and placebo groups using a two-sided chi-square test at the 0.05 significance level. The expected ratios are 50% vs. 15% (guselkumab vs. placebo) for clinical remission and 30% vs. 13% for endoscopic response. The study is sized such that guselkumab therapy achieves >90% power for the co-primary endpoints compared to placebo. This sample size also provides >90% power for all secondary endpoints.
[0238] Efficacy Analysis Continuous variables are summarized using descriptive statistics (e.g., mean, median, standard deviation [SD], interquartile range, minimum, and maximum). Categorical variables are summarized using counts and percentages. Graphical data displays (e.g., line plots) can also be used to summarize the data.
[0239] Analyses appropriate for categorical data (e.g., chi-squared test, or Cochran-Mantel-Haenszel (CMH) chi-squared test or logistic regression, as appropriate) are used to compare the proportion of participants achieving the selected endpoint (e.g., clinical response). Rarely, Fisher's exact test is used for treatment comparisons. Continuous response parameters are compared using analysis of variance (ANOVA) or analysis of covariance (ANCOVA) unless otherwise stated. When the assumption of normality is in question, ANOVA or ANCOVA on van der Waerden normal scores is used.
[0240] Coprimary endpoints (clinical remission at week 12 and endoscopic response at week 12) will be analyzed based on primary estimates, taking into account treatment arms, populations, variables, Intercurrent Events (ICE) strategies, and population-level summaries. After considering the ICE strategy, participants whose responder status for a coprimary endpoint is missing will be considered non-responders for that coprimary endpoint.
[0241] Statistical tests will be performed at a significance level of 0.05 (2-sided). Type I error will be controlled for the coprimary and secondary endpoints. For the coprimary endpoints, clinical remission at week 12 will be examined first, followed by endoscopic response at week 12. The three secondary analyses listed below will be performed sequentially, contingent on the success of both coprimary endpoint analyses. Clinical remission at 24 weeks (CDAI score <150) PRO-2 remission at week 12 (defined as daily mean AP score ≤1 and daily mean stool frequency (SF) score ≤3, i.e., AP ≤1 and SF ≤3, with no worsening of AP or SF from baseline) Clinical response at week 12 (reduction from baseline in CDAI ≥ 100 points or clinical remission) For endpoints where multiplicity was not controlled, apparent p-values are presented.
[0242] Safety analysis Safety data will be summarized, including but not limited to AEs, serious adverse events (SAEs), infections, infection site reactions, changes in laboratory parameters (hematological and chemistry), and suicidal ideation and behavior. All reported treatment-emergent AEs will be included in the analysis.
[0243] Further analysis Pharmacokinetic analysis Serum guselkumab concentrations over time will be summarized for each treatment group using descriptive statistics. Population PK modeling may be performed, where appropriate. If PK analyses of these populations are performed, the results of these analyses will be presented in separate reports.
[0244] Pharmacokinetic / pharmacodynamic analysis The relationship between serum guselkumab concentrations and efficacy measures will be analyzed graphically. Where feasible, suitable exposure-response models will be developed to describe the relationship between serum guselkumab exposure and efficacy. Results of the population PK / PD analysis will be presented in a separate technical report.
[0245] Pharmacogenomics Analysis Genetic (DNA) analyses will be performed only in participants who sign a consent form to participate in the pharmacogenomics substudy. These analyses are considered exploratory and will be documented in a separate technical report.
[0246] Biomarker analysis Where permitted by local regulations, serum protein samples and whole blood ribonucleic acid (RNA) changes obtained over time will be summarized by intervention group. Associations between baseline levels and changes from baseline in selected biomarkers and response to treatment will be examined. RNA analyses will be summarized in a separate technical report.
[0247] Immunogenicity analysis The incidence and titers of antibodies to guselkumab will be summarized for all participants who received guselkumab and had an adequate sample to detect antibodies to guselkumab (i.e., participants with at least one sample obtained after the first dose of guselkumab). The incidence of neutralizing antibodies to guselkumab will be summarized for participants who tested positive for antibodies to guselkumab and had a sample evaluable for neutralizing antibodies to guselkumab.
Claims
1. 1. A method of treating Crohn's disease in a patient, comprising administering to the patient an initial subcutaneous administration of 400 mg of an antibody specific for IL23, a subcutaneous administration of 400 mg about 4 weeks after said initial administration, and a subcutaneous administration of 400 mg about 8 weeks after said initial administration.
2. 10. The method of claim 1, further comprising administering 100 mg or 200 mg of the antibody about every 4 weeks or about every 8 weeks thereafter about 8 weeks after the first administration.
3. 3. The method of claim 2, further comprising administering 200 mg of the antibody about every 4 weeks after the administration about 8 weeks after the first administration.
4. 3. The method of claim 2, further comprising administering 100 mg of the antibody about every 8 weeks after said administration about 8 weeks after said first administration.
5. 2. The method of claim 1, wherein the patient is identified as a responder to the antibody and as meeting a clinical endpoint about 12 weeks after the first administration, wherein the clinical endpoint is clinical remission at week 12 defined as a CDAI less than (<) 150 points or endoscopic response as measured by at least a 50% improvement from baseline in Simplified Endoscopic Crohn's Disease Score (SES-CD).
6. 2. The method of claim 1, wherein the patient is identified as meeting a clinical endpoint, the clinical endpoint being selected from the group consisting of: (i) clinical remission, defined as a CDAI score of less than (<) 150 points measured about 24 weeks after the first dose; (ii) Patient-Reported Outcome (PRO)-2 remission, defined based on a daily average stool frequency (SF) of ≦3 and a daily average abdominal pain (AP) score of ≦1, and no worsening of AP or SF from baseline measured about 12 weeks after the first dose; and (iii) clinical response, defined as a (≧) 100 point or greater reduction from baseline in CDAI score measured about 12 weeks after the first dose.
7. The antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising: The complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4; the CDRL2 amino acid sequence of SEQ ID NO:5, and comprising the CDRL3 amino acid sequence of SEQ ID NO:6, The heavy chain variable region The complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1, The CDRH2 amino acid sequence of SEQ ID NO:2, and 2. The method of claim 1, wherein the antibody comprises a CDRH3 amino acid sequence of SEQ ID NO:3, and the patient is considered a responder to the antibody.
8. The patient is a responder to the antibody and has the following clinical endpoints: (xii) change from baseline in Crohn's Disease Activity Index (CDAI) score; (xiii) clinical remission, defined as a CDAI of less than (<) 150 points; (xiv) clinical response, defined as a reduction from baseline in CDAI score of 100 points or more (≧) or a CDAI score <150; (xv) Patient-Reported Outcome (PRO)-2 remission, defined based on mean daily stool frequency (SF) and mean daily abdominal pain (AP) scores; (xvi) clinical biomarker response, defined using clinical response based on CDAI score and reduction from baseline in C-reactive protein (CRP) or fecal calprotectin; (xvii) endoscopic response as measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD); (xviii) endoscopic remission as measured by Simplified Endoscopic Score for Crohn's Disease (SES-CD); (xiv) sustained clinical remission at Week 48, defined as CDAI<150 for the majority of all visits between Weeks 12 and 48; (xx) Corticosteroid-free clinical remission at Week 48, defined as a CDAI score of <150 at Week 48 and no corticosteroids at Week 48; (xxi) fatigue response based on Patient-Reported Outcomes Measurement Information System (PROMIS); and (xxii) endoscopic response, as measured by Simplified Endoscopic Score for Crohn's Disease (SES-CD) The method of claim 7, wherein the method is identified as satisfying
9. 9. The method of claim 8, wherein the clinical endpoint is measured after 4, 8, 12, 16, 20, 28, 32, 36, 40, 44, and / or 48 weeks of initial treatment.
10. 8. The method of claim 7, wherein the antibody is present in a pharmaceutical composition comprising 7.9% (w / v) sucrose, 4.0 mM histidine, 6.9 mM L-histidine monohydrochloride monohydrate; 0.053% (w / v) polysorbate 80, and the diluent is water at standard conditions.
11. 10. The method of claim 1, further comprising administering to the patient one or more additional drugs used to treat Crohn's disease.
12. 12. The method of claim 11, wherein the additional drug is selected from the group consisting of immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), methotrexate (MTX), anti-B cell surface marker antibodies, anti-CD20 antibodies, rituximab, TNF inhibitors, corticosteroids, and costimulatory regulators.
13. The method of claim 1 , wherein the antibody comprises a light chain variable region amino acid sequence of SEQ ID NO:8 and a heavy chain variable region amino acid sequence of SEQ ID NO:
7.
14. The method of claim 1 , wherein the antibody comprises a light chain amino acid sequence of SEQ ID NO:10 and a heavy chain amino acid sequence of SEQ ID NO:
9.
15. 10. The method of claim 1, wherein the patient is considered a biologic therapy non-responder or intolerant (Bio-non-responder) for Crohn's disease.
16. 2. The method of claim 1, wherein the patient is considered conventional therapy non-responsive or intolerant (Con non-responsive) for Crohn's disease.
17. 2. The method of claim 1, wherein the Crohn's disease is moderate to severe active Crohn's disease.
18. 18. The method of claim 17, wherein the patient has endoscopic evidence of active Crohn's disease prior to administration of the first dose.
19. 18. The method of claim 17, wherein the patient has moderate to severe active Crohn's disease for at least 3 months prior to administration of the first dose.
20. 1. A method of treating moderately to severely active Crohn's disease in a patient, comprising: (i) administering to the patient an initial subcutaneous administration of 400 mg of an antibody specific for IL23, a subcutaneous administration of 400 mg about 4 weeks after said initial administration, and a subcutaneous administration of 400 mg about 8 weeks after said initial administration; and (ii) further administrations of 200 mg of the antibody about 8 weeks after said initial administration and thereafter about every 4 weeks thereafter, or a subcutaneous administration of 100 mg of the antibody about 8 weeks after said initial administration and thereafter about every 8 weeks thereafter, wherein the antibody is selected from the group consisting of SEQ ID NO: and a light chain variable region amino acid sequence of SEQ ID NO:8 and a heavy chain variable region amino acid sequence of SEQ ID NO:7, wherein the patient is a responder to the antibody by being identified as meeting a clinical endpoint about 12 weeks after the first administration, the clinical endpoint being clinical remission at week 12 defined as a CDAI of less than (<) 150 points or endoscopic response as measured by at least a 50% improvement from baseline in Simplified Crohn's Endoscopy Score (SES-CD).
Citation Information
Patent Citations
A safe and effective method for treating psoriatic arthritis with anti-IL23 specific antibodies
JP2021502349A
Treatment method for Crohn's disease using anti-IL-23 specific antibody
JP2021515770A
